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9INTRODUCTION
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Melanoma
Melanoma is an aggressive cancer, arising from a malignant transformation of 
melanocytes. Three major subtypes of melanoma can be characterized: cutaneous 
melanoma, uveal melanoma and mucosal melanoma. 1 Cutaneous melanoma is 
the most common melanoma subtype, accounting for about 90% of melanoma 
cases, and its incidence has been steadily rising since the mid-1960s at a rate faster 
than that of any other malignancy. 1, 2 Unfortunately, melanoma affects a high 
proportion of younger patients, with a median age of diagnosis of 57 years. 1 
Several environmental and genetic risk factors play a role in the development of 
cutaneous melanoma, e.g. cumulative sun exposure, sunburn at younger age, fair 
skin, and high number of (atypical) naevi. 3 The main reason proposed for the 
increasing incidence of cutaneous melanoma is a greater exposure to natural 
ultraviolet (UV) radiation. 3 Uveal and mucosal melanoma are less common and 
show steady incidence rates. 1 
 Cutaneous melanomas are staged by the American Joint Committee on Cancer 
(AJCC) melanoma staging and classification system, which is based on information 
of the primary melanoma, lymph node involvement, and presence of distant 
metastases. 4 Stage I/II disease includes only primary melanomas without lymph 
node involvement or distant metastases. Patients with stage III melanoma have 
loco regional lymph node metastases and/or in-transit metastases, while patients 
with stage IV disease show distant metastases. The focus of this thesis lies on 
stage III and stage IV melanoma.  
Dendritic cells
Dendritic cells (DCs) were first discovered by Steinman and Cohn in 1973. 5 DCs are 
the most potent antigen-presenting cells of the immune system. Under steady 
state conditions, immature DCs sample peripheral tissues in search for pathogens 
or tissue injury, and upon encounter of danger signals, they quickly differentiate 
into activated (mature) DCs and migrate to lymphoid organs to induce an adaptive 
immune response. In lymphoid tissues, mature DCs initiate immune responses by 
presenting captured antigens to naïve T cells, in the form of peptide-major histo-
compatibility complex molecule complexes. These T cells will proliferate and 
differentiate into effector cells that are able to kill cells in an antigen-dependent 
manner. 6 
 Under ideal circumstances, tumor growth will be controlled by an in vivo 
 cancer-immunity cycle, in which DCs take up tumor material and induce tumor- 
specific T cells that infiltrate the tumor bed and kill their target cells by recognition 
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(mDCs): CD1c+ (also known as BDCA1+) mDCs and CD141+ mDCs, which differ in 
function and localization. Activated pDCs secrete large amounts of interferon-α 
(IFN-α) in response to viral products and they can induce the maturation of B cells 
into plasma cells, while mDCs are specialized in immunity against bacteria and 
fungi 6, 12, 20 Until now, pDCs and CD1c+ mDCs have been used in clinical trials with 
advanced melanoma patients. GM-CSF was used to activate CD1c+ mDCs and 
Frühsommer-meningoencephalitis vaccine to activate pDCs. Both mDCs as well 
as pDCs can be loaded with melanoma-associated peptides. 21, 22 
Dendritic cell vaccination in melanoma
Most clinical studies in stage IV melanoma patients were performed with moDCs. 23-27 
Although antigen-specific immune responses were found, long-lasting clinical 
responses were limited in advanced melanoma patients. A recent meta-analysis 
showed a response rate of 8.5% in 1205 advanced melanoma patients treated with 
DC vaccination. 28 The only phase 3 trial comparing moDCs monotherapy with 
dacarbazine in advanced melanoma patients was stopped prematurely due to 
lack of efficacy in both treatment arms. 27 In retrospect, this trial was probably 
performed too early, since DC vaccination was still in development, leading to a 
variable quality of the DC vaccines and suboptimal maturation of DCs. 
 Recently, we have conducted two small proof of principle clinical studies 
exploiting naturally circulating DCs in advanced melanoma patients, the first 
study using pDCs and the second study using CD1c+ mDCs. Tumor-specific T cell 
responses were found after vaccination with both DC populations. Objective 
responses were found in a limited number of patients treated with either subset. 
However, the study with pDCs did show an improved overall survival (OS) for 
patients treated with pDCs as compared with matched historical controls and the 
objective responses and prolonged progression-free survival (PFS) in the mDC 
trial were seen in patients  with functional antigen-specific T cells in blood and 
delayed type hypersensitivity biopsies. 21, 22  
Stage III melanoma patients have a high risk of recurrent disease, even after a 
radical lymph node dissection (RLND) with curative intent. 29 Therefore, adjuvant 
treatments that will improve survival rates are warranted. DC vaccination might 
be more effective in stage III melanoma patients than in stage IV melanoma 
patients, because they may have a more potent immune system than patients 
with advanced disease due to a lower tumor burden. 8 A retrospective analysis of 
78 stage III patients treated with moDCs showed a significant improved OS when 
compared to 209 matched controls who underwent RLND without adjuvant DC 
of specific antigens, thereby releasing new tumor antigens that can be engulfed 
by DCs again. 7 However, in cancer patients, this cycle is hampered: tumor antigens 
may not be detected by DCs, DCs and T cells may treat antigens as self rather than 
foreign, DCs are not adequately stimulated by danger signals, T cells may not 
properly infiltrate tumors, or factors in the tumor microenvironment might suppress 
effector cells, including release of immunosuppressive cytokines, induction of 
regulatory T cells (Tregs) and myeloid derived suppressor cells, and expression of 
immune checkpoint molecules, like cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) and programmed death-1 (PD-1). 7-9 
Dendritic cell vaccines
Therapeutic vaccination, like DC vaccination, can be used to overcome some of the 
aforementioned problems in this cancer-immunity cycle and thus accelerate and 
expand the production of tumor-specific T cells. 7 The first clinical study of a DC 
vaccine was reported in 1996 by Hsu and colleagues in patients with B-cell 
lymphomas. 10 Since then, multiple studies with DC vaccination have been reported 
in various tumor types, e.g. melanoma, prostate cancer, and glioma. 6 Here, we 
will focus on DC vaccination in melanoma patients.
 The goal of DC vaccination is to induce tumor-specific T cell responses by 
injecting activated DCs loaded with tumor antigens. 11 Over the past years, 
different sources of DCs, maturation factors, and ways of tumor antigen loading 
have used in clinical trials in melanoma patients. 12 Until recently, most DCs for 
immunotherapy were in vitro differentiated from precursors like monocytes, by 
culturing them in the presence of interleukin- 4 (IL-4) and granulocyte-macro-
phage colony-stimulating factor (GM-CSF). 13 Additionally, these immature mono-
cyte-derived DCs (moDCs) need to be matured, as mature DCs induce more potent 
anti-tumor immune responses than immature DCs in melanoma patients. 14, 15 
Different methods have been used to mature DCs, including cytokine cocktails 
consisting of monocyte-conditioned medium, tumor necrosis factor-α, prosta -
glandin E2, IL1-1β, and IL-6; prophylactic vaccines as TLR ligands; and electroporation 
with mRNA encoding CD40L, CD70, and constitutively active TLR4. 16-18 Finally, 
the mature DCs must be loaded with relevant tumor-antigens, for which several 
methods have been applied, including short peptides, long peptides, tumor cell 
lysates, and mRNA transfection. 19 
 Recently, naturally circulating DCs have been used to vaccinate advanced 
melanoma patients. Different subsets of naturally circulating DCs can be 
distinguished in the human peripheral blood by the expression of surface 
molecules: BDCA2+ plasmacytoid DCs (pDCs) and two subsets of myeloid DCs 
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vaccination (median OS 63.6 months versus 31.0 months; p=0.018). 30 These results 
need to be confirmed in future clinical trials. 
Therapeutic landscape of stage III and stage IV 
melanoma
Clinical outcomes of new therapeutic agents in stage III and IV melanoma 
patients, including DC vaccination, need to be compared with the results of 
approved therapeutic options. Before 2011, systemic treatment for stage IV 
melanoma consisted of chemotherapy and IL-2, but both treatments have a 
minimal effect on survival. 31 However, during the last years, multiple new 
therapies have been approved for the treatment of advanced melanoma, including 
immune checkpoint inhibitors and targeted therapies. Immune checkpoint 
molecules that down-regulate pathways of T cell activation, like CTLA-4 and PD-1, 
can be blocked with monoclonal antibodies (mAbs; Figure 1). 9 A pooled analysis 
of phase 2-3 trials with the anti-CTLA-4 mAb ipilimumab in advanced melanoma 
patients showed a median OS of 9.5 months with a plateau at 21% in the survival 
curve around 3 years after start of ipilimumab. 32 Trials with the anti-PD-1 mAbs 
nivolumab and pembrolizumab in advanced melanoma patients showed 
approximately two-times higher response rates than ipilimumab and significantly 
longer PFS times. 33, 34 However, long-term survival rates of these anti-PD-1 mAbs 
are still pending. The combination of ipilimumab and nivolumab even resulted in 
an objective response rate of 58%, however, at the expense of significant toxicity. 34 
Besides the immune checkpoint inhibitors, BRAF inhibitors (vemurafenib, 
dabrafenib) have shown significant improvement of PFS and OS in patients with 
an activating BRAF mutation (Figure 1). 35, 36 However, responses are short-lived 
in many patients due to various resistant mechanisms. 37 Recently, it became 
apparent that adding a MEK inhibitor (cobimetinib, trametinib) to a BRAF 
inhibitor was associated with further improvement of survival as compared to 
BRAF inhibition alone (Figure 1), with overall response rates of 64-68% and 
median PFS of 9.3-11.4 months. 38-40  
Until recently, interferon-α (IFN-α) was the only approved adjuvant treatment in 
stage III disease, but IFN-α is not recommend in stage III melanoma patients in 
most European countries, since it only minimally improves survival and comes 
with substantial toxicity. 41 Ipilimumab (10 mg/kg) has recently been approved 
by the Food and Drug Administration based on a significant improvement of 
 recurrence-free survival compared to placebo, but OS data are still awaited. 42 
However, adjuvant ipilimumab induced significant grade 3-4 adverse events and 
Figure 1  Immunotherapy and targeted therapy of melanoma
a  By injecting activated dendritic cells (DCs) loaded with tumor antigens, DC vaccination aims to induce 
tumor associated antigen-specific T cells. Antigen presentation by DCs and co-stimulatory signals 
(B7-CD28) result in T cell activation and proliferation.
b  To keep an immune response in control, CTLA-4 is subsequently up regulated on the surface of T cells, 
which binds stronger to B7 than CD28 and causes an inhibitory signal. Blocking CTLA-4 with 
monoclonal antibodies (ipilimumab) enhances T cell activation. 
c  Binding of PD-1 on the T cells to PD-L1 on the tumor results in downregulation of effector functions of T 
cells, which inhibits the killing of tumor cells. Blockade of this ligation by anti-PD-1 antibodies 
(nivolumab, pembrolizumab) makes it possible for T cells to maintain their antitumor functions, 
which allows them to kill tumor cells.  
d  BRAF is a kinase that is part of the RAS-BRAF-MEK-ERK mitogen-activated protein kinase (MAPK) 
pathway of cell proliferation. The tumors of approximately 40-60% of advanced melanoma patients 
harbor activating BRAF V600 mutations. The mutated kinase is constitutively active, which results in 
unregulated cell proliferation. This process can be blocked by selective BRAF inhibitors (vemurafenib, 
dabrafenib). 
e  Single-agent BRAF inhibition results commonly in progressive disease due to acquired resistance, 
which is commonly caused by genetic escape mechanisms resulting in MAPK pathway independant 
signaling. Upfront inhibition of both MEK (cobimetinib, trametinib) and the mutated BRAF kinases 
might counteract this form of resistance.  
(+) indicates a stimulatory effect; (-) indicates an inhibitory effect. Green round indicates a tumor peptide.
Abbrevations: CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; MHC, major histocompatibility 
complex; PD-1, programmed death-1; PD-L1, programmed death ligand-1; TCR, T cell receptor.
Dendritic cell T cell Tumor cell
TCR  MHC + peptide 
B7  
CD28 (+)  
CTLA-4 (-) 
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Outline of the thesis
The general aim of this thesis is to provide insight in the position of DC vaccination 
in light of the rapidly evolving therapeutic landscape of stage III and stage IV 
melanoma. 
As aforementioned, DC vaccination might be more effective in stage III than in 
stage IV melanoma patients. In chapter 2 a retrospective study is described, which 
investigates the effectiveness of adjuvant DC vaccination to induce tumor-specific 
immunological responses in 97 stage III melanoma patients.  
 It is essential to consider side effects in the choice of the best individual 
treatment plan for each patient, especially when treatments are equally effective 
or when combination therapy is considered. Chapter 3 describes the toxicity profile of 
DC vaccination as monotherapy in a large cohort of stage III and IV melanoma 
patients. Furthermore, we have evaluated the correlation between the occurrence 
of immune-related adverse events of DC vaccination and both immunological 
and clinical outcome.           
 The immunological and clinical effects of DC vaccination might be improved 
by combining it with other therapies. Recently it became evident that the chemo-
therapeutic agent cisplatin has immunomodulatory effects, besides its ability 
to cross-link DNA and inhibition of mitosis. The immunomodulatory effects of 
cisplatin may improve the efficacy of the tumor-specific T cells induced by DC 
vaccination. In chapter 4 we explore whether the combination of DC vaccination 
and cisplatin in stage III and IV melanoma patients is feasible and safe, and if it 
leads to better immunological and clinical responses. 
 Ipilimumab has proven to be effective in stage IV melanoma patients. The order 
in which different treatments are given, might have an influence on the efficacy 
of these therapies. In chapter 5 the efficacy of ipilimumab is determined in advanced 
melanoma patients who showed progressive disease upon DC vaccination, given 
either as adjuvant treatment for stage III disease or for stage IV melanoma.
 The Summarizing discussion, chapter 6, discusses the role of DC vaccination 
in stage III and stage IV melanoma in view of efficacy, toxicity, and other treatment 
modalities. Additionally, it provides future perspectives in DC vaccination in 
melanoma patients. 
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Abstract
Purpose: To determine the effectiveness of adjuvant dendritic cell (DC) vaccination 
to induce tumor-specific immunological responses in stage III melanoma patients.
Experimental design: Retrospective analysis of stage III melanoma patients, 
vaccinated with autologous monocyte-derived DC loaded with tumor-associated 
antigens (TAA) gp100 and tyrosinase after radical lymph node dissection. 
Skin-test infiltrating lymphocytes (SKILs) obtained from delayed-type hyper-
sensitivity skin-test biopsies were analyzed for the presence of TAA-specific CD8+ 
T cells by tetrameric MHC-peptide complexes and by functional TAA-specific 
T cell assays, defined by peptide-recognition (T2 cells) and/or tumor-recognition 
(BLM and/or MEL624) with specific production of Th1 cytokines and no Th2 
cytokines.
Results: Ninety-seven patients were analyzed: 21 with stage IIIA, 34 with stage 
IIIB, and 42 had stage IIIC disease. Tetramer-positive CD8+ T cells were present in 
68 patients (70%), and 24 of them showed a response against all 3 epitopes tested 
(gp100:154-162, gp100:280-288, and tyrosinase:369-377) at any point during 
vaccinations. A functional T cell response was found in 62 patients (64%). Rates of 
peptide-recognition of gp100:154-162, gp100:280-288, and tyrosinase:369-377 were 
40%, 29%, and 45%, respectively. Median recurrence-free survival and distant 
metastasis-free survival of the whole study population were 23.0 months and 
36.8 months, respectively. 
Conclusions: DC vaccination induces a functional TAA-specific T cell response in 
the majority of stage III melanoma patients, indicating it is more effective in stage 
III than in stage IV melanoma patients. Furthermore, performing multiple cycles 
of vaccinations enhances the chance of a broader immune response. 
Introduction
The incidence of stage III melanoma is rising and these patients are at high risk of 
relapse, even after a radical lymph node dissection with curative intention. 1, 2 
Balch and colleagues showed that 5-year survival within substages of stage III 
were 78%, 59%, and 40% for patients with stage IIIA, IIIB, and IIIC melanoma, 
respectively. 3 There is a great medical need for adjuvant treatments that will 
improve survival rates in this population. 3, 4 Until recently, interferon-α was the 
only approved adjuvant treatment, however it minimally improves overall 
survival (OS) and is not recommended in most European countries because of its 
side effect profile. 5 For this reason, other adjuvant therapies are currently under 
investigation, among them ipilimumab 6, programmed death 1 (PD-1) inhibitors 
(NCT02388906, NCT02362594), and vaccination strategies (NCT00796445). Adjuvant 
ipilimumab 10 mg/kg showed a significant improvement of recurrence free 
survival (RFS) compared to placebo, and it has been recently approved by the Food 
and Drug Administration (FDA). However, OS data have not yet been reported 
and treatment was accompanied by significant grade 3-4 toxicity. 6 
 Dendritic cells (DC) are the most efficient antigen-presenting cells of the 
immune system due to their capacity to activate and prime naïve T cells. 7 They 
are essential in the induction of antitumor immunity, and may therefore play a 
vital role in anticancer immunotherapy. 8, 9 DC can be generated ex vivo, activated, 
and loaded with tumor antigens, and then injected into patients. 7, 10 We and others 
have treated stage IV melanoma patients with DC-based vaccines, and noted 
induction of tumor-specific immune responses, but long-lasting clinical responses 
are, thus far, limited. 7, 9, 11, 12 Since high tumor load causes immune suppression by 
secretion of immunosuppressive cytokines, and attraction of regulatory T cells and 
myeloid derived suppressor cells in the tumor microenvironment, DC vaccination 
may be more effective as an adjuvant treatment in stage III patients. 13, 14 
 Because the immunotherapeutic options for melanoma are growing rapidly, 
immunomonitoring of patients is of great importance in these clinical trials. For 
instance, enzyme-linked immunosorbent spot (ELISPOT) assays and flow 
cytometric assays to detect antigen-specific T cells in peripheral blood samples, 
are commonly used in cancer immunotherapy trials. However, since tumor- 
associated antigen (TAA)-specific T cells are detected in only a minority of the 
peripheral blood samples, and to date no correlation has been found between 
immunological data in peripheral blood and clinical outcome, these peripheral 
blood assays might not be optimal for immunomonitoring. 15
 We previously described a bioassay evaluating skin-test infiltrating lymphocyte 
(SKIL) cultures from delayed-type hypersensitivity (DTH) skin-test biopsies after 
DC vaccination in stage IV melanoma patients. 16 The mechanism of action of this 
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Vaccine preparation
Monocytes were enriched from leukapheresis products by plastic adherence of 
blood mononuclear cells or by counterflow centrifugation using Elutra-cell 
separator (Gambro BCT, Lakewood, CO) and single-use, functionally sealed 
disposable Elutra sets, as described before. 21 Monocytes were cultured in the 
presence of IL-4 (500 U/ml), GM-CSF (800 U/ml) (both Cellgenix, Freiburg, 
Germany) and keyhole limpet hemocyanin (KLH; 10 μg/ml, Calbiochem, 
Darmstadt, Germany) or Immucothel KLH (10 μg/ml, Biosyn, Carlsbad, CA). Most 
protocols used DC matured with autologous monocyte-conditioned medium 
(30%, v/v) supplemented with prostaglandin E2 (PGE2; 10 μg/ml, Pharmacia & 
Upjohn, Puurs, Belgium) and 10 ng/ml tumor necrosis factor-α (TNF-α; Cellgenix, 
Freiburg, Germany) for 48 hours or a cocktail of 10 ng/ml TNF-α, 5 ng/ml IL-1β, 
15 ng/ml, IL-6 (all Cellgenix), and 10 μg/ml PGE2. 22, 23 DC in protocols 5 and 8B 
were matured with a cocktail of prophylactic vaccines including BCG vaccine SSI 
(4% v/v, Nederlands Vaccin Instituut, Bilthoven, the Netherlands), Typhim Vi 
(4% v/v, Sanofi Pasteur MSD, Brussels, Belgium), and Act-HIB (4% v/v, Aventis 
Pasteur, Brussels, Belgium), supplemented with PGE2 (10 μg/ml) for 48 h (TLR-DC). 
24 In protocol 8A, DC were matured via electroporation with mRNA encoding 
CD40L, CD70, and constitutively active TLR4. 20 DC were pulsed with two 
gp100-derived peptides (gp100:154-162 and gp100:280-288) and a tyrosinase- 
derived peptide (tyrosinase:369-377) or electroporated with mRNA encoding 
gp100 or tyrosinase. 25 Quality control of DC was performed as described before. 12 
Cells were resuspended and injected intradermally, or intranodally, or 
intradermally and intravenously. Patients received a maximum of 30 x 106 DC 
intradermally, 15 x 106 intranodally, or 10 x 106 DC intradermally plus 20 x 106 
intravenously per vaccination.
KLH-specific proliferation 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood 
by Ficoll-Paque density centrifugation, and stimulated with KLH (4 μg/2×105 
PBMC) in X-VIVO with 2% human serum (HS). After 3 days, cells were incubated 
with 3H-thymidine for 8 hours and incorporation was measured with a β-counter. 
Experiments were performed in sextuplicate, non-specific proliferation upon 
stimulation with ovalbumin was used as control. Proliferative response to KLH is 
given as proliferation index (proliferation with KLH/proliferation without KLH).
KLH-specific antibody production
KLH-specific antibodies were measured in the sera of patients before and after 
vaccination by ELISA (www.klhanalysis.com). Briefly, microtiter plates (96 wells) 
were coated overnight at 4°C with KLH (25 μg/ml in PBS per well). After washing 
bioassay is based on the fact that tumor-specific T cells should be able to invade 
peripheral tissues, recognize tumor antigens, proliferate, and deliver a functional 
response upon tumor-specific stimulation. Antigen-specific T cells which are also 
able to migrate to peripheral tissues are selected when a DTH with TAA-loaded DC 
is used. After short-time culturing of these SKILs from DTH skin biopsies, they are 
challenged by target cells loaded with defined tumor peptides and target cells 
that express naturally processed tumor antigens. 10, 16
 The aim of this retrospective study was to explore the effectiveness of 
adjuvant DC vaccination to induce tumor-specific immunological responses in 
stage III melanoma patients. 
Materials and Methods
Patient characteristics
We retrospectively analyzed a cohort of 99 stage III melanoma patients, who were 
enrolled in our DC vaccination studies between December 1999 and July 2014. 
Patients received adjuvant DC vaccination within 2 months after radical lymph 
node dissection. Inclusion criteria included melanoma with histologically proven 
regional metastatic disease without evidence of distant metastases; World Health 
organization (WHO) performance status of 0 or 1; HLA-A*02:01 phenotype; and 
histological proven melanoma expressing the melanoma-associated antigens 
gp100 (compulsory) and tyrosinase (non-compulsory). Patients with a second 
malignancy in the previous 5 years or serious concomitant disease were excluded. 
At least one DTH must have been performed to be included in this analysis, since 
the goal was to evaluate tumor-specific immunological responses. All studies 
were approved by the appropriate Medical Ethical Review Board and written 
informed consent was obtained from all patients.
Treatment schedule
All patients were vaccinated with autologous monocyte-derived DC loaded with 
TAA of gp100 and tyrosinase according to a schedule of 3 biweekly vaccinations, 
followed by a DTH skin test within 2 weeks after each vaccination cycle. Some 
patients received an extra vaccination before radical lymph node dissection for 
additional imaging studies. Patients received 3 cycles of vaccinations and a DTH 
skin-test at approximately 6-month intervals when no signs of distant metastases 
were present. Differences in protocols included the route of administration, 
method of antigen loading, and combination treatment with interleukin (IL)-2 or 
cisplatin (Table 1). For the exact details of the vaccination protocols we refer to 
these individual studies. 12, 17-20 
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A positive result was defined as a two-fold increase compared to stimulation 
with the same cell lines pulsed with an irrelevant peptide. 
SKIL culture evaluation
SKILs were evaluated according to 2 criteria. At first, the presence of TAA-specific 
CD8+ T cells, recognizing the predefined epitopes, by tetrameric MHC-peptide 
complexes. Secondly, the occurrence of a functional TAA-specific T cell response 
was measured, defined by peptide-recognition (T2 cells) and/or tumor-recognition 
(BLM and/or Mel624) with specific production of Th1 cytokines and no Th2 
cytokines. 
Statistical analysis
RFS, distant metastasis-free survival (DMFS) and OS were calculated from the 
date of apheresis to the date of first recurrence, distant metastases and death, 
using the Kaplan-Meier method. Additionally, a conditional landmark analysis 
was performed to evaluate the effect of the occurrence of (functional) TAA-specific 
T cells on survival. Hazard ratios and associated 95% CI were assessed with the 
use of a Cox proportional-hazards model. A paired t-test was used to compare 
KLH proliferation in time. Ulceration was assumed absent if not reported in the 
pathology report. P-values less than 0.05 were considered significant. SPSS version 
20.0 software (SPSS Inc, Chicago, IL) and Graphpad Prism 5.03 (GraphPad Software 
inc, San Diego, CA) were used for statistical analysis.
Results
Patient and vaccine characteristics 
The aim of this study was to evaluate immunological responses to DC vaccination. 
Since the DTH skin-test biopsies were taken after each cycle of three vaccinations, 
patients should have had completed at least one cycle to be immunologically 
evaluable. In total, 97 out of 99 (98%) HLA*02:01-positive stage III melanoma 
patients met this criterion. Baseline characteristics of the evaluable patients are 
listed in Table 1. Overall, 21 patients (22%) had stage IIIA, 34 (35%) had stage IIIB, 
and 42 (43%) had stage IIIC disease. The phenotype of the generated DC (expression 
of MHC class I/II and co-stimulatory molecules) was determined by flow cytometry 
and the produced vaccines met the quality release criteria (Supplementary 
Figure 1A). 11 Flow cytometry showed intracellular expression of both TAA (gp100 
and tyrosinase) in DC electroporated with mRNA (Supplementary Figure 1B). 
The median follow-up time from apheresis to patient death or censoring was 
47.4 months (range 3.7-168.6 months).
the plates, patient serum was added in duplicate for 1 hour at room temperature. 
After extensive washing, patient KLH-specific antibodies were detected with 
mouse anti-human IgG, IgA or IgM antibodies labeled with horseradish peroxidase 
(Invitrogen, Waltham, USA). 3,3’ 5,5-tetramethyl-benzidine (Dako, Glostrup, 
Denmark) was used as a substrate and plates were measured in a microtiter plate 
reader at 450 nm. For quantification an isotype-specific calibration curve for the 
KLH response was included in each microtiter plate. 26
Skin-test infiltrating lymphocyte culture
Previously we observed that, in a series of patients who underwent pre-vaccination 
skin test analysis, none of the patients had detectable levels of TAA-specific 
T cells prior to vaccination. Therefore pre-vaccination skin-tests were not performed, 
and we focused on in-depth analysis on the post-vaccination samples. Skin tests 
were performed within 2 weeks after each vaccination cycle as described 
previously. 10, 16 Briefly, a maximum of 10x105 DC loaded with either gp100, 
tyrosinase or both antigens were injected intradermally in the skin of the back of 
patients at different sites, 4 cm apart from each other. After 48 hours, punch 
biopsies (6 mm) were taken. Half of the biopsy was stored and half manually cut 
and cultured for 2-4 weeks in RPMI-1640 containing 7% HS and IL-2 (100 U/ml). 
Tetramer staining of SKILs
SKIL cultures were stained with tetrameric-MHC complexes containing the HLA-
A*02:01-binding epitopes gp100:154-162, gp100:280-288, or tyrosinase:369-377 
as described previously. 10 Tetrameric major histocompatibility complex (MHC) 
complexes recognizing HIV were used as correction for background binding. 
Tetramer positivity was defined as at least two-fold increase in the double positive 
population compared to an irrelevant control antigen (HIV).
Functionality of SKILs
The production of T-helper (Th)1 (IFN-γ and IL-2) and Th2 (IL-4 and IL-5) cytokines 
by SKILs was measured in supernatants after 16 hours of co-culture with different 
target cells, to obtain a cytokine profile of post-vaccination SKILs. IL-4 production 
was not available for all patients. The target cells were T2 cells pulsed with 
gp100:154-162, gp100:280-288, and tyrosinase:369-377; BLM (a melanoma cell line 
expressing HLA-A*02:01 and no endogenous expression of gp100 and tyrosinase), 
transfected with control antigen G250, gp100 or tyrosinase; and an allogenic 
HLA-A*02:01-positive, gp100-positive, and tyrosinase-positive tumor cell line 
(Mel624). Cytokine analysis was done by cytometric bead array (Th1/Th2 Cytokine 
CBA 1; BD Pharmingen, San Diego, CA or human Th1/Th2 FlowCytomix multiplex 
kit; eBioscience, Vienna, Austria), according to the manufacturer instructions. 
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since 2 of these patients had TAA-specific T cells in DTH skin-test biopsies. The above 
described results show that the majority of this patient population is well capable 
of  inducing an immune response against the control antigen KLH.
Immunological responses to KLH
Immunological responses to KLH were used as a surrogate marker for immune 
competence. After vaccination, patients were assessed for the presence of 
KLH-specific T cells in their PBMC and for antibody responses against KLH in 
their serum. After the first round of vaccinations, an increased T cell proliferation 
upon stimulation with KLH was found in 68 out of 80 patients (85%) tested 
(Supplementary Figure 2) and anti-KLH antibodies (IgG, IgA and/or IgM) were 
detected in 62 out of 80 patients (78%) tested. Only 4 patients (4%) showed no 
increased KLH-specific T cell- or anti-KLH antibody-response. This was not 
associated with the incapacity to develop a TAA-specific CD8+ T cell response, 
Table 1  Dendritic cell vaccination protocols
Protocol Number  
of patients
Method of  
antigen loading
Route of 
administration
IL-2a Cisplatin
1 1 Peptide: class I modb i.n. no no
2A 10 Peptide: class I wtc i.d. yes no
2B 8 Peptide: class I wtc i.n. yes no
2C 10 Peptide: class I wtc i.n. no no
2D 10 Peptide: class I wtc i.d. no no
2E 10 mRNAd i.n. no no
4A 4 Peptide: class I wtc + IIe i.n. no no
4B 3 Peptide: class I wtc i.n. no no
4C+D 16 mRNAd i.n. no no
5A 5 mRNAd i.v./i.d. no no
8A+B 4 mRNAd i.n. no no
9C 9 mRNAd i.v./i.d. no yesf
9D 7 mRNAd i.v./i.d. no no
Total 97
a  Low-dose IL-2 (9 MIU) was administered subcutaneously once daily for 1 week starting 3 days after 
each vaccination.
b  Class I mod; HLA class I-restricted modified gp100-derived peptides 154-162 Q A and 280-288 A V and 
HLA class I-restricted tyrosinase-derived peptide 369-377 
c  Class I wt; HLA class I-restricted wild-type gp100-derived peptides 154-162 and 280-288 and HLA class 
I-restricted tyrosinase-derived peptide 369-377 
d  mRNA; messenger RNA encoding full length gp100 and tyrosinase 
e  Class II; HLA class II-restricted gp100-derived peptide 44-59 and tyrosinase-derived peptide 448-462 
analog
f  Cisplatin (50 mg/m2) was administered intravenously before each vaccination. 
Abbreviations: wt, wild type; mod, modified; i.d., intradermal; i.n., intranodal; i.v., intravenous; IL-2, 
Interleukin-2.
Figure 1  Tumor antigen-specific CD8+ T cell responses in SKIL cultures
An example is shown of a tetramer analysis of SKILs from patient II-D-12 (A). Cells were stained with 
tetramers encompassing the peptides gp100:154, gp100:280, tyrosinase or an irrelevant peptide 
(control) and with anti-CD8 mAb. This analysis showes presence of TAA-specific CD8+ T cells against 
both gp100 epitopes and tyrosinase. Furthermore, a cytokine profile of the same T cells is shown after 
stimulation with T2 cells loaded with gp100 or tyrosinase peptide, BLM cells transfected with gp100 or 
tyrosinase, or MEL624 cells expressing both gp100 and tyrosinase (B). Functional TAA-specific T cells 
against gp100 and tyrosinase are present with a clear production of IFN-γ and/or IL-2, but without IL-5 
production.
A
B
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Presence of TAA-specific CD8+ T cells 
DTH skin-test biopsies were taken within 2 weeks after each cycle of vaccinations 
in all patients, and after short-time culture they were analyzed for the presence of 
TAA-specific CD8+ T cells by tetrameric MHC-peptide complexes (Figure 1). The 
presence of TAA-specific CD8+ T cells recognizing any epitope (gp100:154-162, 
gp100:280-288, or tyrosinase:369-377) in SKIL cultures was shown in 68 patients 
(70%). A total of 24 patients (25%) had TAA-specific CD8+ T cells against all 
3 epitopes, 27 patients (28%) showed tetramer-positive CD8+ T cells recognizing 
2 epitopes, and there were 17 patients (17%) with T cells against only 1 epitope. 
Fifty-two patients (54%) had T cells against the epitope gp100:154-162, 51 patients 
(53%) T cells against gp100:280-288, and 40 patients (41%) against tyrosinase:369-
377. In the majority of patients (72%), tetramer-positive T cells against any epitope 
were observed after the first cycle of vaccinations. Furthermore, 16  patients (24%) 
expanded their tetramer-positive T cell response after cycles 2 and 3. However, a 
notable portion of 72 patients with data available of consecutive rounds, lacked 
tetramer-positive T cells against an epitope after a positive result in a previous 
cycle; 29% for gp100:154-162, 35% for gp100:280-288, and 18% for tyrosinase:369-
377 (Figure 2A). 
 Furthermore, the DTH skin-test biopsies were analyzed for the occurrence of 
a functional TAA-specific T cell response (Figure 1), by measuring specific 
production of Th1/Th2 cytokines in response to T2 cells pulsed with gp100:154-162, 
gp100:280-288, or tyrosinase:369-377 (peptide-recognition), BLM transfected with 
gp100/tyrosinase and Mel624 (tumor-recognition). A functional TAA-specific T 
cell response (peptide-recognition and/or tumor-recognition) was found in 62 
patients (64%), of whom 60 patients (97%) showed tetramer-positive T cells. Rates 
of peptide-recognition of gp100:154-162, gp100:280-288, and tyrosinase:369-377 
were 40%, 29%, and 45%, respectively. Tumor-recognition was found in 47 patients 
(49%), of whom 25 patients showed a functional response against Mel624. As with 
the test using tetrameric MHC-peptide complexes, in some patients the functional 
assay for peptide-recognition showed no functional T cells after a positive result 
in a previous cycle; 6% for gp100:154-162, 8% for gp100:280-288, and 6% for 
tyrosinase:369-377 (Figure 2B).    
 Besides the DTH skin-test biopsies, peripheral blood samples were analyzed 
for the occurrence of TAA-specific CD8+ T cells by tetrameric MHC-peptide 
complexes, and they were found in only 15 patients (15%) at any point during 
vaccinations. All these patients also showed tetramer-positive CD8+ T cells in the 
DTH skin-test biopsies.
Figure 2  SKILs analysis in time
Skin-test infiltrating lymphocytes from DTH skin-test biopsies were analyzed for the presence of te-
tramer-positive CD8+ T cells (A) and a functional T cell response against individual epitopes (B). Three 
epitopes were tested, gp100:154, gp100:280, and tyrosinase. Unfilled/filled circles represent  negative/
positive tests. The black, red, and blue circles match to the first, second, and third cycle of vaccinations, 
respectively. Tumor-specific T cells are already seen after the first cycle in a large amount of patients. T 
cells against other epitopes were detected in a proportion of patients after cycle 2 and 3. However, in 
some patients T cells against an epitope were not detected after a positive result in the previous cycle. 
This is more often seen for tetramer-positive T cells than for a functional T cell response. The distant 
metastasis-free survival (DMFS) of each individual patient is shown with a cut-off at 5 years. Arrows 
indicate an ongoing DMFS.
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Survival
Median RFS and distant metastasis-free survival (DMFS) of the whole study 
population were 23.0 months (95% confidence interval (CI), 9.6-36.4 months) and 
36.8 months (95% CI, 21.0-52.7 months), respectively. Significant differences in 
DMFS were found between the absence or presence of ulceration and between the 
different AJCC pathological stages (Supplementary Table 1). A trend towards an 
improved DMFS was seen in patients with tetramer-positive T cells at any point 
during vaccinations, compared to patients without tetramer-positive T cells; 
median DMFS 44.2 months (95% CI, 2.2-18.0 months) versus 10.1 months (95% CI, 
25.9-62.5 months; p=0.056). The same trend was found for a functional T cell 
response at any point during vaccinations; median DMFS 44.2 months (95% CI, 
26.5-61.9 months) versus 14.0 months (95% CI, 7.7-20.3 months; p=0.066). However, 
for tetramer-positive T cells, as well as for a functional T cell response, this trend 
Figure 3  Analyses of distant metastasis-free survival
A graphical representation of the hazard ratios (HR) of distant metastasis-free survival (DMFS) 
comparing patients with or without tetramer-positive and a functional T cell response in DTH skin-test 
biopsies, using Cox proportional-hazard models. HR less than 1 defines a better DMFS for patients with 
tumor-specific T cells. Horizontal lines represent 95% confidence intervals. A trend for a lower risk of 
distant metastases is seen for patients with tetramer-positive T cells and a functional T cell response at 
any point during the vaccinations as compared with patients without a T cell response. However, 
conditional landmark analyses after cycle 1 (n=97), cycle 2 (n=72), and cycle 3 (n=56) show no difference 
in risk of distant metastases between patients with or without tetramer-positive T cells and a functional 
T cell response.
Table 2  Baseline characteristics
Dendritic cell vaccinated stage III  
melanoma patients
n=97 (%)
Sex
Male
Female
60
37
(62)
(38)
Age, years
Mean (range) 50.6 (22-79)
Age in categories, years
21-30
31-40
41-50
51-60
≥61
4
19
23
31
20
(4)
(20)
(24)
(32)
(21)
Breslow thickness primary melanoma, mm
≤1.0 
1.01-2.0
2.01-4.0
>4.0
No primary/unknown
7
26
25
31
8
(7)
(27)
(26)
(32)
(8)
Ulceration of primary melanoma
Absent
Present 
68
29
(70)
(30)
Histological type melanoma
Superficial spreading
Nodular
Acral lentiginous
Lentigo maligna
Spitzoid
No primary/unknown
54
22
1
1
2
17
(56)
(23)
(1)
(1)
(2)
(18)
N stage at inclusion
N1a
N1b
N2a
N2b
N3
24
24
5
14
30
(25)
(25)
(5)
(14)
(31)
AJCC pathological stage
IIIA
IIIB
IIIC
21
34
42
(22)
(35)
(43)
Adjuvant radiotherapya
No
Yes
91
6
(94)
(6)
a Adjuvant radiotherapy was given after the apheresis, but before the first vaccination.
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more epitopes. Furthermore, because of epitope spreading the tumor-specific 
immune response might also be more widespread in patients vaccinated with 
peptide-pulsed DC. 27 Besides using tetrameric MHC-peptide complexes, this SKIL 
analysis integrates the measurement of cytokine profiles, and therefore it is 
possible to differentiate between Th1 and Th2 immune responses. Th1-type 
cytokines are important in pro-inflammatory cellular responses, which are 
desirable for anti-tumor immunity, while Th2-type cytokines are more involved 
in anti-inflammatory responses.28 A functional T cell response, defined as specific 
production of Th1 cytokines and no Th2 cytokines in response to antigen-express-
ing target cells, was found in 64% of patients, which is clearly more frequent 
compared to patients with distant metastases receiving DC vaccinations (23%). 29 
A total of 40% of stage III patients already had a functional T cell response after 
the first cycle of vaccinations, indicating that the observed difference is not solely 
explained by more cycles of vaccinations. In addition, considerable more stage III 
than stage IV patients showed a broader immune response; tetramer-positive 
CD8+ T cells recognizing multiple epitopes were found in 52% and 14% of patients, 
respectively. 29 Of course, false-positivity must always be considered in diagnostic 
tests, but the chance of false positive results is assumed to be low since the 
different assays include negative controls as comparison. The occurrence of an 
adequate T cell response is negatively influenced by many factors, like immuno-
suppressive cytokines, immune checkpoints, regulatory T cells, and myeloid-de-
rived suppressor cells. These factors are more frequently observed in patients with 
a higher tumor burden, and interact at different levels of the cancer immunity 
cycle, e.g. priming, activation, and proliferation of T cells, and infiltration of T cells 
in the tumor. 14, 30 In conclusion, DC vaccination is more effective in producing a 
tumor-specific T cell response in stage III than in stage IV melanoma patients.    
 Part of the patients with tetramer-positive T cells or a functional T cell 
response against a tumor-specific peptide did not show these T cells in the DTH 
skin test after a subsequent cycle of vaccinations. First, this might be caused by a 
low sensitivity of the test with false-negative results. Second, it might indicate 
that there is a lack of induction of memory in these patients. A final reason that 
TAA-specific T cells are no longer detected might be the absence of in vivo 
stimulation of these T cells by tumor cells, which might have been killed during 
the previous cycle.    
 A trend towards a better DMFS was found in patients with a tumor-specific 
T cell response at any point during vaccinations, when compared to patients 
without TAA-specific response. However, this difference might be explained by 
guarantee-time bias, since DMFS is compared across groups defined by an event 
occurring sometime during follow-up. 31 Therefore, a conditional landmark 
analysis was performed after each cycle of vaccinations to correct for this type of 
was no longer present when a conditional landmark analysis was performed 
after each cycle of vaccinations in order to correct for potential guarantee-time 
bias, in which only patients were analyzed who completed that cycle (Figure 3).
 Fifty-eight patients (60%) developed distant metastases, of whom 33 patients 
(57%) received some form of systemic treatment. Chemotherapy (DTIC) was given 
to 22 patients (67%), while 10 patients (17%) received ipilimumab and 5 patients 
(8%) targeted agents, because a considerable part of these patients was treated at 
a time when immune checkpoint inhibitors and targeted therapies were not yet 
available. At the time of data cut-off 48 deaths had occurred, and the median OS 
of the whole study population was 77.7 months (95% CI, 48.1-107.3). 
Discussion
Immunomonitoring is an important part of evaluating the effectiveness of 
immunotherapy. Besides peripheral blood samples, SKILs cultured from vaccine- 
challenged biopsies were used to detect TAA-specific T cells. The results of the here 
presented study show that a TAA-specific T cell response can be induced in the 
majority of stage III melanoma patients treated with adjuvant DC vaccination 
following a radical lymph node dissection. 
 Using SKIL cultures could have some advantages compared to commonly 
used tetramer analysis or ELISPOT assays of TAA-specific T cells in peripheral 
blood. First of all, SKIL cultures select TAA-specific T cells which are able to 
extravasate and migrate into peripheral tissues, while it is unknown if 
TAA-specific T cells in peripheral blood have these capabilities. Furthermore, 
peripheral blood samples show a lower prevalence of TAA-specific T cells, probably 
because most T cells are gathered in the lymphoid organs. Therefore, SKILs from 
DTH skin-test biopsies may be more suitable for immunomonitoring than PBMC 
in DC vaccinated patients, despite the fact that these biopsies are more time-
consuming.
 SKILs were evaluated according to the presence of TAA-specific CD8+ T cells by 
tetrameric MHC-peptide complexes. Tetramer-positive T cells recognizing one or 
more epitopes were found in 70% of patients, of whom a vast majority already 
showed T cells against an epitope after the first cycle of vaccinations. Furthermore, 
the chance of a broader immune response is enhanced by performing multiple 
cycles of vaccinations, because T cells against other epitopes were detected for 
the first time after the following cycles in many patients with tetramer-positive 
T cells during a previous cycle. Tumor-specific T cell responses might be more 
extensive than only against the 3 HLA-A*02:01-binding epitopes tested,  especially 
in patients vaccinated with DC electroporated with mRNA, since these DC present 
34 35
CHAPTER 2 TUMOR-SPECIFIC IMMUNE RESPONSES IN ADJUVANT DC VACCINATION
2
Acknowledgements
The authors thank the patients who participated in the studies and JFM Jacobs for 
analyzing antibody responses against KLH.
 Financial support: This work was supported by grants from the Dutch Cancer 
Society (KUN2009-4402), a Radboudumc PhD grant and the stichting Afweer 
Tegen Kanker (ATK). C.F. received the NWO Spinoza award and an ERC Advanced 
grant. IJMdV received a NWO-VICI grant (918.14.655)
bias, and this showed no difference in DMFS between the 2 groups. Therefore, it 
cannot be concluded that a tumor-specific T cell response in DTH skin-test biopsies 
can be used as a predictive marker for clinical outcome, despite the recognized 
disadvantages of a conditional landmark analysis, like the omission of events 
occurring earlier to the landmark. 32 
 We already showed a favorable OS in stage III melanoma patients treated 
with adjuvant DC vaccination, compared to matched controls. 33 Of course, no hard 
conclusions can be drawn from the retrospective data we present here, but in 
comparison to the EORTC phase 3 trial with adjuvant ipilimumab (10 mg/kg), both 
studies show comparable 3-year RFS rates (43% in our cohort versus 46.5% in the 
ipilimumab group), which is at least promising. 6 A disadvantage of adjuvant 
ipilimumab is the toxicity profile, with grade 3-4 adverse events occurring in 54% 
of patients and 52% who stopped the treatment due to side-effects. 6 This in strong 
contrast to DC vaccination, where grade 3-4 toxicity is rarely observed. 9 There is a 
risk of selection bias in the present study, since only patients were included in 
whom at least one DTH was performed. However, in only 2 out of 99 patients, DTH 
skin biopsies were not taken because of early relapse of disease after vaccinations 
were started. A prospective randomized clinical trial is necessary to determine 
the exact position of adjuvant DC vaccination in stage III melanoma patients.
 The clinical effectiveness of DC vaccination might be improved by increasing 
the number of antigens. The melanoma differentiation antigens gp100 and 
tyrosinase were selected because they are commonly expressed on melanoma 
cells and have shown to be capable of inducing functional cytotoxic T cells. 12, 34, 35 
However, recent findings show that tumor-specific mutations, leading to 
neoantigens, may drive potent antitumor responses. 36 Carreno and colleagues 
found that a DC vaccine with carefully selected patient-specific neoantigens, led 
to an increase in the breadth and diversity of melanoma neoantigen-specific T 
cells in peripheral blood samples of 3 stage IV melanoma patients. 37 As most 
mutated proteins are essentially unique to a tumor, personalized antigen selection 
might be beneficial in vaccination strategies. 36, 37 A great challenge will be the 
identification of the right immunogenic neoantigens, especially in stage III 
melanoma patients, since only a minimal amount of tumor material might be 
available. 38 For this reason, and in light of tumor heterogeneity, it might be 
preferable to combine commonly expressed melanoma differentiation antigens 
with patient-specific neoantigens in future DC vaccines.
 In summary, DC vaccination is more effective in inducing functional TAA- 
specific CD8+ T cells in stage III than stage IV melanoma patients, and performing 
multiple cycles of vaccinations enhances the chance of a broader immune 
response. A prospective randomized clinical trial must determine the exact 
position of adjuvant DC vaccination in stage III melanoma patients. 
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Supplementary material
Supplementary Table 1  Univariate analysis of distant metastasis-free survival
n Median DMFS 
(months)
HR 95% CI P value
 Sex
Male
Female
60
37
40.2
38.8
1
1.001 0.59-1.70 0.998
Age in categories, years
21-30
31-40
41-50
51-60
≥61
4
19
23
31
20
24.0
Not reached
33.0
43.0
9.7
1
0.445
1.282
1.202
1.721
0.09-2.21
0.29-5.62
0.28-5.12
0.39-7.64
0.322
0.742
0.804
0.475
Breslow thickness primary melanoma, mm
≤1.0 
1.01-2.0
2.01-4.0
>4.0
No primary/unknown
7
26
25
31
8
19.2
Not reached
33.0
23.4
Not reached
1
0.596
0.945
1.430
0.567
0.19-1.87
0.32-2.83
0.50-4.13
0.13-2.54
0.375
0.919
0.509
0.458
Ulceration of primary melanomaa
Absent
Present 
68
29
59.9
16.0
1
2.051 1.21-3.49 0.008
AJCC pathological stage
IIIA
IIIB
IIIC
21
34
42
Not reached
50.4
14.0
1
4.092
9.415
1.39-12.06
3.31-26.78
0.011
<0.001
Adjuvant radiotherapy
No
Yes
91
6
40.8
9.9
1
2.623 0.92-7.51 0.072
Vaccination + IL-2
No
Yes
79
18
36.3
40.8
1
1.060 0.56-2.00 0.858
a If not mentioned in pathology report: no ulceration.
Supplementary Figure 1  Vaccine characteristics
A. Phenotype of the generated DC (expression of MHC class I/II and co-stimulatory molecules). 
B.  Intracellular expression of both gp100 and tyrosinase in DC electroporated with mRNA.
Supplementary Figure 2  KLH-specific T cell proliferation
Mean KLH-specific proliferation index before and after the first cycle of vaccinations in PBMC. 
*, p<0.0001.
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Abstract
The purpose was to determine the toxicity profile of dendritic cell (DC) vaccination 
in stage III and IV melanoma patients, and to evaluate if there is a correlation 
between side effects and immunological and clinical outcome. This is a 
retrospective analysis on toxicity profiles of 82 stage III and 137 stage IV melanoma 
patients, vaccinated with monocyte-derived or naturally circulating autologous 
DCs loaded with tumor-associated antigens gp100 and tyrosinase. Median 
follow-up time was 54.3 months  in stage III patients and 12.9 months in stage IV 
patients. Treatment-related adverse events occurred in 84% of patients; grade 3 
toxicity was present in only 3% of patients. Most common adverse events were 
flu-like symptoms (67%) and injection site reactions (50%), and both correlated 
with the presence of tetramer-positive CD8+ T cells (both p<0.001). In stage III 
melanoma patients experiencing flu-like symptoms median overall survival (OS) 
was not reached versus 32.3 months in patients without flu-like symptoms 
(p=0.009); median OS in patients with an injection site reaction was not reached 
versus 53.7 months in patients without an injection site reaction (p<0.05). In stage IV 
melanoma patients (primary uveal and mucosal melanomas excluded), median 
OS in patients with or without flu-like symptoms was 13.1 versus 8.9 months, 
respectively (p=0.03); median OS in patients with an injection site reaction was 
15.7 months versus 9.8 months in patients without an injection site reaction 
(p=0.003). In conclusion, DC vaccination is safe and tolerable and the occurrence 
of the immune-related side effects, such as flu-like symptoms and injection site 
reactions, correlates with immunological and clinical outcome.
Introduction
Melanoma is considered to be one of the most immunogenic tumors and is 
susceptible to immunotherapy.1 Immunotherapeutic approaches consist of immune 
checkpoint inhibitors, cytokines, and vaccination strategies.2 The vaccination 
strategy studied by our group is dendritic cell (DC) vaccination. DCs were first 
discovered by Ralph Steinman in 1973, and play a crucial role in the induction of 
antitumor immunity.3 Autologous DCs can be generated ex vivo, activated, and 
loaded with tumor antigens, and then injected into patients with the intention to 
induce tumor-specific effector T cells to kill tumor cells and induce immunological 
memory to control tumor relapse.4, 5 We and others have treated stage III and IV 
melanoma patients with DC-based vaccines in different trials over the past years, 
and noted numerous tumor-specific immune responses. Long-lasting clinical 
responses are, thus far, limited in stage IV patients treated with DC vaccination 
monotherapy.6, 7 Intriguingly, in a retrospective study with stage III patients, who 
received autologous DCs loaded with gp100 and tyrosinase, overall survival (OS) 
was significantly better compared with matched controls, but these results have 
to be confirmed in a prospective randomized clinical trial.8 
 As in the field of melanoma therapeutic options are growing rapidly, the 
choice of the right individual treatment plan for each patient is becoming more 
challenging. Amongst the currently approved treatments for metastastic 
melanoma are the immune checkpoint inhibitors ipilimumab, nivolumab and 
pembrolizumab9-12, the BRAF-inhibitors vemurafenib13, and dabrafenib, and the 
MEK-inhibitor trametinib.14 Stage III melanoma patients are at high risk of relapse, 
despite a radical lymph node dissection, and until recently there was a lack of 
an effective adjuvant systemic treatment.15, 16 In 2015, the Food and Drug 
Administration gave approval for adjuvant ipilimumab (10 mg/kg), based on 
improvement of recurrence-free survival (RFS) compared with placebo in a phase 
III trial.17 However, data on OS have not been reported yet. Anti-PD-1 monoclonal 
antibodies (mAbs) are currently under investigation in stage III melanoma 
patients (NCT02388906, NCT02362594). The probability of a durable clinical 
response is certainly the most important factor in the choice of treatment in stage IV 
melanoma patients in a good clinical condition. Furthermore, it is essential to 
consider side effects in treatment decisions, especially when treatments are 
equally effective or when combination therapy is considered. Trials with 
ipilimumab and anti-PD-1 mAbs showed considerable grade 3-4 adverse events, 
particularly when the combination of both treatments was given.9, 12, 17, 18 
Immune-related adverse events, such as colitis and dermatitis, are the most 
common forms of toxicity after checkpoint inhibition. Attia and colleagues 
showed a correlation between the induction of autoimmunity and durable 
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objective responses in patients treated with anti-cytotoxic T-lymphocyte 
antigen-4 (CTLA-4) in combination with peptide vaccination. A partial or complete 
response was seen in 36% of patients with grade 3-4 autoimmune toxicity, 
compared with 5% of patients with no signs of autoimmunity.19 Furthermore, a 
recent meta-analysis including 5737 stage III/IV melanoma patients treated with 
immunotherapy showed that vitiligo was associated with a clear survival 
benefit.20 Therefore, we hypothesized that there might also be a correlation 
between immune-related side effects and immunological and clinical outcomes 
in DC vaccinated patients.
 The aim of this retrospective study was to determine the toxicity profile of DC 
vaccination in a large cohort of stage III and IV melanoma patients, and to evaluate 
if there is a correlation between the occurrence of immune-related adverse events 
and both immunological and clinical outcome.       
Material and Methods
Patient characteristics 
We retrospectively analyzed a cohort of  stage III and stage IV melanoma patients, 
who were enrolled in our DC vaccination trials between June 1999 and March 
2014. Stage III patients received adjuvant DC vaccination within 2 months after 
radical lymph node dissection. DC vaccination in stage IV patients was given as 
any line of treatment, although mostly as first line treatment. Inclusion criteria 
were: histologically proven regional (stage III) or distant (stage IV) metastastic 
disease; World Health organization (WHO) performance status of 0 or 1; and 
melanoma expressing the melanoma-associated antigens gp100 (compulsory) 
and tyrosinase (noncompulsory). Patients with a second malignancy in the 
previous 5 years or serious concomitant disease were excluded. All studies were 
approved by the appropriate Medical Ethical Review Board and written informed 
consent was obtained from all patients.
Dendritic cell vaccination
All patients were vaccinated with DCs loaded with tumor-associated antigens 
(TAA) of gp100 and tyrosinase according to a schedule of 3 biweekly vaccinations, 
followed by a delayed type hypersensitivity (DTH) skin test within 2 weeks after 
each vaccination cycle. Some patients received an extra vaccination before radical 
lymph node dissection for additional imaging studies. Patients received a 
maximum of 2 additional cycles of vaccinations at 6-month intervals when no 
signs of recurrent or progressive disease were present. 
 Patients were treated with DC vaccination monotherapy in different treatment 
protocols (Table 1). DC vaccination is still an investigational product in melanoma. 
Stage III patients were all vaccinated with monocyte-derived autologous DCs 
(moDCs), as were most stage IV patients. Monocytes were enriched from 
leukapheresis products by plastic adherence of blood mononuclear cells or by 
counterflow centrifugation using Elutra-cell separator (Gambro BCT, Lakewood, 
CO) and single-use, functionally sealed disposable Elutra sets, as described 
before.21 Monocytes were cultured in the presence of interleukin (IL)-4 (500 U/ml), 
granulocyte macrophage colony-stimulating factor (GM-CSF) (800 U/ml, both 
Cellgenix, Freiburg, Germany), and keyhole limpet hemocyanin (KLH) (10 μg/ml, 
Calbiochem, Darmstadt, Germany or Immucothel, Biosyn Arzneimittel GmbH, 
Fellbach, Germany). Most protocols used DCs matured with autologous mono-
cyte-conditioned medium (30%, v/v) supplemented with prostaglandin E2 (PGE2)
(10 μg/ml, Pharmacia & Upjohn, Puurs, Belgium) and tumor necrosis factor-α 
(10 ng/ml, Cellgenix) for 48 hours or a cocktail of tumor necrosis factor-α (10 ng/ml), 
IL-1β (5 ng/ml), IL-6 (15 ng/ml, all Cellgenix) and PGE2 (10 μg/ml).22 DCs in protocols 
5 and 8B were matured with a cocktail of prophylactic vaccines including BCG 
vaccine SSI (4% v/v, Nederlands Vaccin Instituut, Bilthoven, the Netherlands), 
Typhim Vi (4% v/v, Sanofi Pasteur MSD, Brussels, Belgium), and Act-HIB (4% v/v, 
Aventis Pasteur, Brussels, Belgium), supplemented with PGE2 (10 μg/mL) for 
48 hours (VAC-DC).23 In protocol 8A, DCs were matured via electroporation with 
mRNA encoding CD40L, CD70, and constitutively active TLR4.24 DCs were pulsed 
with MHC-I-restricted peptides gp100:154-162 , gp100:280-288 and tyrosinase: 
369-377, or electroporated with mRNA encoding gp100 or tyrosinase.25 DCs in 
protocol 4A were also pulsed with MHC-II-restricted peptides gp100:44-59 and 
tyrosinase:448-462.7
 A minority of stage IV patients were treated with naturally occurring 
plasmacytoid DCs (pDCs) or myeloid DCs (mDCs).26, 27 pDCs and mDCs were directly 
isolated from apheresis products using the fully closed immunomagnetic CliniMACS 
isolation system (Miltenyi Biotec, Bergisch Gladbach, Germany). GMP-grade 
magnetic bead-coupled antibodies were used, following the manufacturer’s 
guidelines. Following apheresis and CliniMACS isolation, pDCs and mDCs were 
cultured overnight at a concentration of 106 cells/mL in X-VIVO 15 (Cambrex, East 
Rutherford, NJ) containing pooled human serum (2%, Sanquin, Amsterdam, the 
Netherlands), supplemented with recombinant human IL-3 (10 ng/mL, Cellgenix) 
for pDCs, and recombinant human GM-CSF (800 U/ml, Cellgenix) and KLH (1 mg/
ml, Immucothel, Biosyn Arzneimittel GmbH, Fellbach, Germany) for mDCs. pDCs 
were activated by addition of FSME-IMMUN (1:10 v/v; Baxter AG, Vienna, Austria). 
pDCs and mDCs were loaded with the melanoma- associated HLA-A*0201-restrict-
ed peptides gp100:154-162, gp100:280-288, and tyrosinase:369-377.  
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Toxicity and response evaluation
Safety evaluations were performed at the out-patient clinic in all patients before 
each vaccination, DTH, and 2 follow-up visits. Adverse events were scored using 
the National Cancer Institute Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.03. Grade 3 and 4 adverse events were considered to be serious 
adverse events. Flu-like symptoms include fever, fatigue, chills, body aches, 
malaise, loss of appetite and headache. Fatigue was mentioned separately when it 
lasted at least one day longer than the other flu-like symptoms or when present 
without other flu-like symptoms.
 Tumor evaluation was performed at baseline and every 3 months by physical 
examination in stage III patients and by CT-scan according to RECIST version 1.1 in 
stage IV patients. DTH skin-tests were used for immunological response evaluation 
in all treatment protocols. Briefly, DCs loaded with either gp100, tyrosinase or 
both antigens were injected intradermally in the skin of the back of patients at 
different sites, 4 cm apart from each other (max. 1x106 DC each). After 48 hours, 
punch biopsies (6 mm) were taken. Skin-test infiltrating lymphocytes (SKILs) 
were analyzed for antigen-specific T cells by staining them with tetrameric-ma-
jor histocompatibility complex (MHC) complexes containing the gp100 and 
tyrosinase epitopes (HLA-A*02:01  positive patients) and TAA-specific functional 
responses by specific production of type 1 T helper (Th1) cytokines and no type 2 T 
helper (Th2) cytokines to TAA, as described before.28
Statistical analysis
OS was calculated from the date of apheresis to the date of death. The Kaplan-Meier 
method was used to evaluate the correlation between adverse events and clinical 
outcome. Primary uveal and mucosal melanomas were excluded from survival 
analyses of stage IV patients to improve uniformity. Statistical significance was 
evaluated using a log-rank test. Cox proportional-hazard models were used to 
estimate hazard ratios (HR). Cramér’s V scores (measure of association between 
nominal variables) were calculated to measure the association between the 
occurrence of adverse events and immunological outcome; Pearson’s chi-square 
tests were used to evaluate statistical significance. Ulceration was assumed 
absent if not reported in the pathology report. P-values less than 0.05 were 
considered significant. SPSS version 22 software (SPSS Inc, Chicago, IL) and 
Graphpad Prism 5.03 (GraphPad Software inc, San Diego, CA)  were used for 
statistical analysis. 
Results 
Patient characteristics
A total of 82 stage III and 137 stage IV melanoma patients treated with DC 
vaccination monotherapy between June 1999 and July 2015, were included in the 
analysis. DCs were predominantly administered intranodally (64%), and the 
most commonly used method of antigen loading was electroporation with mRNA 
(52%, Table 1). Patient characteristics of all included patients are listed in Table 2. 
All stage III patients were treated with moDCs, while in patients with stage IV 
disease, 79% received moDCs, 11% were treated with pDCs, and 10% of patients 
with mDCs. A total of 59% of stage III patients and 10% of stage IV patients 
Table 1  Dendritic cell vaccination protocol
Protocol Number of  
melanoma patients
Type  
of DC
Method of antigen 
loading
Route of 
administration
Stage III Stage IV
1B 1 9 moDC Peptide: class I moda i.n. (1x) or i.v./i.d.
1C 0 13 moDC Peptide: class I wtb i.v./i.d.
2C 10 2 moDC Peptide: class I wtb i.n.
2D 10 1 moDC Peptide: class I wtb i.d.
2E 10 1 moDC mRNAc i.n.
4A 5 11 moDC Peptide: class I wtb + IId i.n.
4B 3 11 moDC Peptide: class I wtb i.n.
4C+4D 16 18 moDC mRNAc i.n.
5 8 11 moDC mRNAc i.n. (1x) or i.v./i.d.
6A+6DE 0 15 pDC Peptide: class I wtb i.n.
6B 0 14 mDC Peptide: class I wtb i.n.
8 8 15 moDC mRNAc i.n.
9 11 16 moDC mRNAc i.v./i.d.
Total 82 137
a  Class I mod; HLA class I-restricted modified gp100-derived peptides 154-162 Q A and 280-288 A V and 
HLA class I-restricted tyrosinase-derived peptide 369-377 
b  Class I wt; HLA class I-restricted wild-type gp100-derived peptides 154-162 and 280-288 and HLA class 
I-restricted tyrosinase-derived peptide 369-377 
c mRNA; messenger RNA encoding full length gp100 and tyrosinase 
d  Class II; HLA class II-restricted gp100-derived peptide 44-59 and tyrosinase-derived peptide 448-462 
analog
Abbreviations: DC, dendritic cell; moDC, monocyte-derived autologous DC; pDC, plasmacytoid DC; mDC, 
myeloid DC; wt, wild type; mod, modified; i.d., intradermal; i.n., intranodal; i.v., intravenous. 
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completed all 3 cycles of vaccinations, 20% of patients with stage III disease and 
7% of stage IV patients received 2 cycles, and only 1 cycle was given to 22% of stage III 
patients and 83% of stage IV patients. The median follow-up time from apheresis 
to patient death or censoring was 54.3 months (range 3.7-162.4 months) in stage III 
patients and 12.9 months (range 2.0-179.7 months) in stage IV patients.
Toxicity profile
A total of 183 patients (84%) had any treatment-related adverse event. The adverse 
events reported are listed in Table 3. The most common adverse events related to 
DC vaccination were flu-like symptoms (67%) and injection site reactions (50%). 
Flu-like symptoms usually lasted up to 48 hours and consisted of fever, fatigue, 
chills, body aches, malaise, loss of appetite and headache, although generally only 
a few of these symptoms were present. Significantly more stage III than stage IV 
patients had flu-like symptoms (77% vs. 61%, p=0.024) and injection site reactions 
(71% vs. 37%, p<0.001). When flu-like symptoms were present, they occurred 
already during the first cycle in 87% of stage III and 93% of stage IV patients. 
Of patients with an injection site reaction, 68% of stage III and 97% of stage IV 
patients showed this during the first cycle of vaccinations. Stage IV patients with 
a raised lactate dehydrogenase (LDH) at baseline, a bad prognostic factor,29 showed 
less injection reactions than patients with a normal LDH (10% vs. 29%, p=0.021), 
but no difference was seen for flu-like symptoms (p=0.457). Treatment-related 
grade 3 adverse events were present in 3% of patients, consisting of hepatitis 
Table 2  Patient characteristics 
Stage III patients  
(n=82)
Stage IV patients  
(n=137)
Sex
Male
Female
55 (67%)
27 (33%)
85 (62%)
52 (38%)
Age (years)
Mean (range) 50.4 (22-72) 52.9 (19-76)
Site of primary melanoma
Skin
Mucosal
Eye 
Unknown primary
75 (91%)
0
0
7 (9%)
108 (79%)
3 (2%)
15 (11%)
11 (8%)
AJCC pathological stage at time of inclusion
IIIA
IIIB
IIIC
IV
17 (21%)
32 (39%)
33 (40%)
0
0
0
0
137 (100%)
M stage at time of inclusionb,c
M1a
M1b
M1c
n.a.
26 (19%)
38 (28%)
72 (53%)
Systemic line of treatment DC vaccination  
for stage IV disease
First
Second 
Third
Fourth
n.a.
121 (88%)
14 (10%)
1 (1%)
1 (1%)
Systemic therapy following DC vaccination  
for stage IV disease
No systemic therapy
Chemotherapy
Ipilimumab
Anti-PD1
Targeted therapy
50 (61%)
16 (20%)
13 (16%)
4 (5%)
11 (13%) 
52 (38%)
50 (37%)
30 (22%)
5 (4%)
24 (18%)
a  If not mentioned in pathology report: no ulceration.
b  M-staging is different in uveal melanoma compared to skin melanomas. The appropriate American 
Joint Committee on Cancer (AJCC) TNM system was used for both skin and uveal melanomas. 
c  One patient in stage IV group with an inoperable stage III.
Abbreviations: n.a., not applicable
Table 3  Adverse events 
Event Stage III melanoma 
(n=82)
Stage IV melanoma 
(n=137)
Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3
Any event 68 (83%) 14 (17%) 4 (5%) 100 (73%) 27 (20%) 4 (3%)
Any treatment-related event* 68 (83%) 13 (16%) 2 (2%) 98 (72%) 25 (18%) 4 (3%)
Flu-like symptomsa 39 (48%) 23 (28%) 1 (1%) 61 (45%) 22 (16%) 0
Injection site reaction 50 (61%) 8 (10%) 0 40 (29%) 11 (8%) 0
Nausea 16 (20%) 0 0 9 (7%) 2 (2%) 0
Anorexia 11 (13%) 0 0 9 (7%) 1 (1%) 0
Fatigueb 5 (6%) 1 (1%) 0 11 (8%) 4 (3%) 0
Coughc 2 (2%) 2 (2%) 0 5 (4%) 1 (1%) 0
Rash 3 (4%) 5 (6%) 0 1 (1%) 0 0
Vomiting 1 (1%) 0 0 6 (4%) 1 (1%) 0
Hepatitis 0 0 1 (1%) 1 (1%) 1 (1%) 4 (3%)
Dyspnoeac 1 (1%) 2 (2%) 1 (1%) 2 (2%) 0 1 (1%)
Dizziness 3 (4%) 0 0 4 (3%) 0 0
Vitiligo 1 (1%) 0 0 3 (2%) 0 0
*attributed by investigator
a  Flu-like symptoms include fever, fatigue, chills, body aches, malaise, loss of appetite and headache.
b  Fatigue was mentioned separately when it lasted at least one day longer than the other flu-like 
symptoms or when it was present without the other flu-like symptoms.
c  Pneumonitis was diagnosed in 4 patients with cough and dyspnoea, and suspected in 2 other patients.
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(5 patients), pneumonitis (2 patients), and flu-like symptoms (1 patient). All grade 
3 adverse events were seen in patients treated in protocols 5 and 8B who received 
DCs matured with cocktail of prophylactic vaccines.30 Vaccinations were stopped 
due to toxicity in 3 patients (1%) of these protocols and other patients in these 
protocols received no subsequent cycles or received a dose reduction. In only 
2 patients (1%) in the other vaccination protocols, vaccinations were stopped on 
patients request due to a temporary grade 2 rash.  
 As aforementioned, 29 stage IV patients received naturally circulating DCs 
intranodally, while the other 108 stage IV patients received moDCs intranodally, 
intradermally, or intravenously and intradermally. Patients receiving naturally 
circulating DCs experienced significantly less treatment-related adverse events 
compared to patients treated with moDCs (59% vs. 85%, p=0.008). Injection site 
reactions and flu-like symptoms were less present in patients treated with 
naturally circulating DCs in comparison with patients treated with moDCs; 7% 
versus 45% (p=0.001) and 28% versus 69% (p<0.001), respectively. Although 
intranodal administration induced less immune-related adverse events compared 
to intravenous/intradermal administration (p<0.001), significant differences in 
injection site reactions and flu-like symptoms remained when natural DCs were 
only compared with intranodally injected moDCs; 7% versus 55% (p<0.001) and 
28% versus 64% (p=0.001), respectively.
 In conclusion, DC vaccination is safe and tolerable in both stage III and IV 
melanoma patients and naturally circulating DCs induces less immune-related 
adverse events than moDCs.
Immune-related adverse events correlate with immunological  
en clinical outcome
DTH skin-tests were performed after each cycle of vaccinations, in which punch 
biopsies were taken 48 hours after injecting DCs loaded with either gp100, 
tyrosinase or both antigens. Lymphocytes out of these biopsies (SKILs) were tested 
for antigen-specific T cells by staining them with tetrameric-MHC complexes 
containing the gp100 and tyrosinase epitopes in 178 HLA-A*02:01 positive stage III 
and IV patients. Furthermore, SKILs of 207 patients were available for analysis of 
TAA-specific functionality. Tetramer-positive CD8+ T cells were found in SKILs of 
85 patients (48%), and in 68 patients (33%) a functional response was present. 
A significant correlation was found between the occurrence of flu-like symptoms 
and presence of tetramer-positive CD8+ T cells (Cramér’s V 0.264, p<0.001) or a 
TAA-specific functional T cell response (Cramér’s V 0.239, p=0.001). A correlation 
was also found between injection site reactions and the presence of tetramer- 
positive CD8+ T cells (Cramér’s V 0.303, p<0.001) or a TAA-specific functional T cell 
response (Cramér’s V 0.257, p<0.001). 
 Median OS in all stage III patients was 81.2 months. OS was significantly 
longer in 63 stage III patients (77%) with flu-like symptoms (any grade) compared 
to 19 patients (23%) without these symptoms (HR 0.43; 95% confidence interval 
(CI), 0.22-0.83; p=0.012), with a corresponding median OS of not reached versus 
32.2 months (95% CI, 7.1-55.3; p=0.009; Figure 1A). Similarly, a longer OS was found 
in 58 stage III patients (71%) with an injection site reaction (any grade) compared 
to 24 patients (29%) without an injection site reaction (HR 0.53; 95% CI, 0.28-1.00; 
p=0.053); median OS was not reached versus 53.7 months (95% CI, 2.8-104.7; p<0.05; 
Figure 1B). The correlation between flu-like symptoms and OS remained, when 
only 48 patients, who completed 3 cycles of vaccinations, were analyzed (HR 0.24; 
95% CI, 0.09-0.65; p=0.005); median OS was not reached in 38 patients with 
flu-like symptoms versus 53.7 months (95% CI, 8.6-98.9) in 10 patients without 
these symptoms (p=0.002). A trend for a better OS in 38 patients with an injection 
site reaction was seen (HR 0.41, 95% CI, 0.15-1.11; p=0.078). 
Figure 1  Immune-related adverse events correlate with clinical outcome
Kaplan-Meier curves of overall survival (OS) according to different side effects. The occurrence of 
flu-like and injection site reactions correlate significantly with OS in stage III (A+B) and stage IV (C+D) 
melanoma patients. Patients with a primary uveal or mucosal melanoma were excluded from this 
analysis.
A
C
B
D
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 Median OS in 119 stage IV patients, with a primary cutaneous melanoma or 
unknown primary, was 11.3 months. As in stage III patients, flu-like symptoms 
and injection site reactions correlated with OS in stage IV patients; HR 0.66 (95% 
CI, 0.45-0.97; p=0.033) and HR 0.55 (95% CI, 0.37-0.83; p=0.004), respectively. 
Median OS in 71 patients (60%) with flu-like symptoms was 13.1 months (95% CI 
10.1-16.1) versus 8.9 months (95% CI, 4.4-13.3) in 48 patients (40%) without these 
symptoms (p=0.03; Figure 1C). In patients with (35%) or without (65%) an injection 
site reaction, median OS were 15.7 months (95% CI, 11.3-20.1) and 9.8 months (95% 
CI, 7.2-12.4; p=0.003; Figure 1D), respectively. The correlation between injection 
site reactions and OS remained when a conditional landmark analysis was 
performed after the first cycle of vaccinations (HR 0.62; 95% CI, 0.42-0.94; p=0.022), 
while it was no longer seen for flu-like symptoms (HR 0.94; 95% CI, 0.64-1.38; 
p=0.754). A significant difference in OS between patients with or without an 
injection site reaction remained when only patients with a normal LDH were 
analyzed (median OS 16.3 months vs. 10.7 months, p=0.01).
 In conclusion, immune-related adverse events correlate with immunological 
and clinical outcome in stage III and IV melanoma patients. 
Discussion
This analysis of a large patient cohort shows that DC vaccination in stage III and 
IV melanoma patients is tolerable and safe. Furthermore, it indicates that the 
occurrence of immune-related adverse events correlates with immunological and 
clinical outcome. 
 The most common treatment-related adverse events of DC vaccination were 
grade 1-2 flu-like symptoms and injection site reactions at the place of intradermal 
or intranodal vaccination. Flu-like symptoms lasted up to 48 hours and patients 
were allowed to take acetaminophen to minimize complaints. Injection site 
reactions, consisting of redness, swelling, pain and itch, were usually small and 
self-limiting within 2-7 days. Patients, treated with naturally circulating DCs, 
experienced significantly less injection site reactions and flu-like symptoms than 
patients receiving moDCs. This difference might be explained by the amount of 
DCs per vaccination, an average of 6x106 mDCs or 2.6x106 pDCs per vaccination 
versus up to 30x106 moDCs. However, naturally circulating DCs could induce less 
side effects themselves independent of the number of injected cells. Treatment- 
related grade 3 adverse events occurred only in 3% of patients; amongst them 
5 patients with hepatitis and 2 patients with an interstitial pneumonitis. All these 
patients were treated in protocols using a cocktail of prophylactic vaccines as TLR 
ligands to mature the DCs, which generates mature DCs that produce IL-12 and 
optimizes T cell help.23 The BCG vaccine was probably the reason for these side-
effects.30 Despite frequent induction of immune responses, this form of DC 
maturation will not be used in future trials due to its toxicity. So, DC vaccination 
monotherapy gives mild toxicity and can safely be administered in stage III and 
IV melanoma patients.
 Flu-like symptoms and injection site reactions are considered to be immune- 
related side effects and they showed a weak, yet significant, correlation with the 
presence of tetramer-positive CD8+ T cells and a TAA-specific functional T cell 
response in stage III and IV patients combined. This correlation does not prove 
that these side effects are solely caused by activated TAA-specific T cells. 
Theoretically, KLH-specific responses may have played a role in the occurrence of 
immune-related side effects. However, no correlation was found between the 
degree of T cell proliferation upon stimulation with KLH and these adverse events 
(data not shown). Furthermore, it is possible that the presence of these 
immune-related adverse events may indicate a more general raised immune 
activation, which might be beneficial for a good TAA-specific T cell response. This 
would be an explanation for the observation that patients with distant metastases 
showed less flu-like symptoms and injection site reactions than stage III melanoma 
patients, since these patients have a more immunosuppressive environment due to 
a higher tumor burden.31, 32 
 The occurrence of adverse events at any point during the vaccinations 
correlated with an improved OS in both stage III and stage IV patients. However, 
there is a risk for guarantee-time bias when correlating side effects with survival, 
since patients who completed more cycles of vaccinations may have had a higher 
chance of developing side effects.33 To correct for this possible bias, we performed 
a conditional landmark analysis in stage III patients after the third cycle of 
vaccinations, in which only patients were included who completed 3 cycles. The 
correlation between flu-like symptoms and survival remained in this analysis 
and a clear trend was still observed for injection site reactions. In stage IV patients, 
a conditional landmark analysis was performed after the first cycle of vaccinations, 
since the majority of patients only received one cycle of vaccinations, and it 
showed a remaining correlation between the presence of an injection site reaction 
and OS, while it was not detected for flu-like symptoms. This indicates that the 
correlation between flu-like symptoms at any point during the vaccinations and 
OS might have been caused by guarantee-time bias. In conclusion, stage III and IV 
melanoma patients with immune-related adverse events of DC vaccination show 
a better immunological and clinical outcome.    
 Toxicity profiles play an important role in the choice of treatment for 
individual melanoma patients with the upcoming of many new agents. Hodi et al 
showed grade 3-4 adverse events in 20-25% of stage IV melanoma patients treated 
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with ipilimumab and death related to the study drugs in 2.1% of patients.9 In a 
phase III trial in stage III melanoma patients treated with adjuvant ipilimumab, 
49% of patients discontinued treatment because of therapy-related adverse events 
and 5 participants (1%) died due to drug-related adverse events.17 Studies with 
anti-PD-1 mAb in metastatic melanoma showed a favourable toxicity profile 
compared to ipilimumab. However, toxicity was still substantial with grade 3-4 
adverse events in 10-16% of patients, and one treatment-related death was noted 
in the first-line nivolumab trial.12, 18 Immune-related adverse events, e.g. colitis, 
dermatitis, hepatitis and hypophysitis, are the most common side effects of these 
checkpoint inhibitors.34 As aforementioned, DC vaccination shows minimal 
toxicity compared to the checkpoint inhibitors, which could be explained by the 
fact that DC vaccination, in contrast to checkpoint inhibitors, induces an anti-
gen-specific immune response instead of stimulating the immune system in 
general. In stage IV melanoma patients the search for effective combinations of 
treatments is warranted, while ipilimumab and anti-PD-1 mAb result in long-term 
survival in a minority of patients.9, 12, 18 However, more severe adverse events can 
occur when therapies are combined. Recent examples of increased toxicity of 
combination-therapy are a phase 3 trial with ipilimumab and nivolumab, with 
55% grade 3-4 adverse events, and a phase 1 trial with vemurafenib and 
ipilimumab, which was terminated due to hepatic toxicity.18, 35 With currently 
available treatment options, DC vaccination monotherapy is not preferred in 
stage IV melanoma patients, since it sporadically gives long-lasting clinical 
responses.6, 7 However, DC vaccination might be a good candidate to combine with 
checkpoint inhibitors, both seen from a toxicity as well as from a immune 
modulating perspective. Checkpoint inhibitors block immune checkpoints, like 
CTLA-4 and PD-1, which could attenuate proliferation and effector function of 
tumor-specific T cells induced by DC vaccination.36 A recent phase 2 study 
combining autologous DCs and ipilimumab in pretreated advanced melanoma 
patients showed that the combination was tolerable and resulted in an 
encouraging overall response rate of 38%.37 Currently, no trials with a combination 
of DC vaccination and anti-PD-1 mAb are ongoing in melanoma patients, but there 
are trials in progress with this combination in other tumor types, e.g. brain 
tumors (NCT02529072). The results on efficacy of a prospective randomized 
clinical trial with adjuvant DC vaccination in stage III patients have to be awaited, 
before this mild toxicity profile can plead for DC vaccination in these patients.
 In conclusion, DC vaccination is safe and tolerable, and it shows much less 
toxicity compared with immune checkpoint inhibitors currently available or in 
trial in both stage III and IV melanoma patients. Furthermore, the occurrence of 
the immune-related adverse events flu-like symptoms and injection site reactions 
correlates with immunological and clinical outcome.
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Abstract
Background: Autologous monocyte-derived dendritic cell (DC) vaccines can induce 
tumor-specific T cells, but these immune responses can be counteracted by immuno-
suppressive mechanisms. Cisplatin has shown immunomodulatory effects in vitro, 
and may therefore have an additive effect on DC vaccination in melanoma patients.
Methods: Prospective, randomized, open label phase 2 study, including stage III/
IV melanoma patients receiving 3 biweekly vaccinations of gp100/tyrosinase 
mRNA-loaded DCs with or without prior administration of cisplatin (50 mg/m2, 
maximum of 100 mg/dose). Primary objectives were the immunogenicity and 
feasibility of cisplatin, and secondary objectives toxicity and clinical outcome.
Results: Twenty-two stage III and 32 stage IV patients were included for analysis. 
Patients receiving DC vaccination with cisplatin did not show more tumor-specific 
tetramer-positive CD8+ T cells (50% versus 61%) or functional T cell responses 
(36% versus 24%) in skin-infiltrating lymphocytes, compared to DC vaccination 
monotherapy. One therapy-related grade 3 adverse event (4%) occurred after 
combination treatment and no grade 3-4 adverse events after monotherapy. 
In stage III patients, median recurrence-free survival was not reached after 
combination treatment, compared to 10.9 months in the group with DC mono - 
therapy (p=0.137). In stage IV patients, median progression-free survival was 
4.7 months after combination treatment versus 3.0 months in the group without 
cisplatin (p=0.101).
Conclusions: Combination of DC vaccination and cisplatin in stage III/IV melanoma 
patients is feasible and safe, but does not result in more tumor-specific T cell 
responses when compared to DC vaccination monotherapy. Together with the 
data on clinical outcome, these results do not appear to justify the use of DC 
vaccination combined with cisplatin in this setting. 
Introduction
Dendritic cells (DCs) are the most efficient antigen-presenting cells of the immune 
system due to their capacity to activate and prime naïve T cells, and for that 
reason, they are ideal to be exploited for vaccination therapy. 1 Studies with 
autologous monocyte-derived DC vaccines have shown tumor-specific immune 
responses in stage III and IV melanoma patients. However, objective clinical 
responses are found in a minority of stage IV melanoma patients treated with DC 
vaccination. 2-4 In stage III melanoma patients who received adjuvant DC 
vaccination, we found a favorable overall survival compared to matched controls, 
but these results have to be confirmed in a prospective randomized phase 3 trial. 5
 The efficacy of DC vaccination in melanoma patients may be improved by 
combination with other treatments. Platinum-based compounds, a type of 
chemotherapy, are widely used for several forms of cancer. 6, 7 The oldest platinum 
compound, cisplatin, was first administered to a patient in 1971 and became 
available for general oncology practice in 1978. 6 Cisplatin was also tested in 
metastatic melanoma patients, either as monotherapy or in combination with 
other types of chemotherapy, interferon (IFN) or interleukin (IL)-2, but without 
great clinical benefit. 8-10 However, it has become apparent that besides its ability 
to cross-link DNA and inhibit mitosis, cisplatin also has immunomodulatory 
effects. 11 Cisplatin might have an additive effect on DC vaccination in melanoma 
patients for the following reasons. First, experiments in vitro showed that cisplatin 
causes loss of STAT6 phosphorylation, which results in downregulation of T 
cell-inhibitory molecule programmed death ligand 2 (PD-L2) on both DCs and 
tumor cells. PD-L2 downregulation results in enhanced tumor cell recognition by 
T cells. 7, 12 Second, more recently preclinical studies showed that cisplatin may 
improve the ability of cytotoxic T cells to recognize cancer cells by upregulating 
MHC class I expression on tumor cells. Additionally, cisplatin may improve 
recruitment and proliferation of T cells and it may cause upregulation of the lytic 
activity of cytotoxic effector cells. Furthermore, cisplatin causes downregulation 
of the immunosuppressive tumor microenvironment by reducing levels of 
 myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). 11, 13 
Finally, contrary to previous reports, we recently observed that cisplatin is able of 
inducing immunogenic cell death (ICD). (Di Blasio, Oncoimmunology, in press) ICD 
is a mechanism whereby chemotherapy results in an adaptive immune response 
through a combination of three characteristics, which might potentiate the 
immune response caused by DC vaccination. Firstly, an endoplasmatic reticulum 
stress response results in the exposure of calreticulin on the cell surface. 
This gives an “eat me” signal to DCs and macrophages. Secondly, the release of 
adenosine triphosphate from apoptotic cells recruits DCs to the tumor site and 
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induces their activation. Finally, this process results in the release of histone 
 chromatin-binding protein high mobility group box 1 from the nucleus of the cell, 
which further enhances DC activation and cross-presentation.  14
 Combining DC vaccination with cisplatin may have a synergistic effect, as 
the immunomodulatory effects of cisplatin may improve the efficacy of the 
 tumor-associated antigen (TAA) specific T cells induced by DC vaccination. Van 
der Sluis and colleagues recently showed synergy between vaccination with 
synthetic long peptides (SLP) of human papillomavirus type 16 (HPV16) and 
cisplatin in a preclinical tumor model for HPV16. Combined treatment led to 
highly infiltrated tumors with HPV-specific tumor necrosis factor-α (TNF-α) and 
IFN-γ producing T cells, and it showed significantly decreased tumor cell 
proliferation compared to single treatment. 15 To our knowledge, no clinical trials 
have been published yet, combining DC vaccination with cisplatin.
 The aim of this study was to explore whether the combination of autologous 
monocyte-derived DC vaccination and cisplatin in stage III and IV melanoma 
patients is feasible and safe, and if it leads to better immunological and clinical 
responses compared to monotherapy with DCs.
Materials and Methods
Patient characteristics
Patients between 18 and 70 years of age were eligible for enrollment if they 
had histologically confirmed stage III cutaneous or stage IV cutaneous, uveal or 
unknown primary melanoma. Additional key eligibility criteria included: World 
Health Organization performance status of 0 or 1; melanoma expressing the 
 melanoma-associated antigens gp100 (compulsory) and tyrosinase (non-compulsory); 
normal serum lactate dehydrogenase (LDH) level; serum creatinine level of less 
than 150 μmol/L; start of adjuvant DC vaccination within 2 months of radical 
lymph node dissection (RLND) in stage III patients; and at least one measurable 
target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1 in stage IV patients. Exclusion criteria were: any prior chemotherapy, 
immunotherapy, or radiotherapy within 4 weeks of the first vaccination; brain 
metastases; a history of any second malignancy in the previous 5 years; serious 
active infections or autoimmune disease; and a known allergy to shell fish. 
The study was approved by the appropriate Medical Ethical Review Board and 
written informed consent was obtained from all patients. Clinical registration 
number is NCT0228541.
Study design and treatment
In this prospective, open label phase 2 study, stage III and IV melanoma patients 
were randomly assigned to receive either autologous monocyte-derived DC 
vaccination with cisplatin or DC vaccination alone in a 1:1 ratio. Patients were 
stratified for HLA-A*02:01 status and stage. All patients were vaccinated with 
autologous cytokine-matured monocyte-derived DC electroporated with mRNA 
encoding the TAA gp100 and tyrosinase, and pulsed with keyhole limped 
hemocyan (KLH) protein. Patients received 3 biweekly vaccinations, followed by a 
delayed-type hypersensitivity (DTH) skin-test within 1-2 weeks. In absence of 
disease progression, patients received 2 additional cycles of vaccinations at 
6-month intervals. The vaccinations were given both intradermally and 
intravenously. In the combination arm, each DC vaccination was preceded by 
cisplatin intravenously (50 mg/m2, with a maximum of 100 mg per dose), 1-2 
hours before DC injection. The dose of cisplatin was based on in vitro experiments, 
in which different doses of cisplatin were used to evaluate its effect on cytokine 
production of moDCs. 12 Cisplatin (50 mg/m2) is considered to be high-emetoge-
nous chemotherapy and therefore the standard antiemetic regime consisted of 
dexamethasone intravenously (10 mg on day 1), apprepitant orally (125 mg on day 
1 and 80 mg on days 2+3), and ondansetron intravenously (8 mg on day 1). Since 
February 2014, the dexamethasone regime changed to 12 mg orally on day 1-4. 
Primary endpoints of the study were immunological responses and the feasibility 
of technical and clinical implementation of combined cisplatin and DC 
vaccination. Patients were considered to be evaluable when at least one DTH 
skin-test was performed. Secondary objectives were toxicity and survival, 
consisting of recurrence-free survival (RFS), progression-free survival (PFS), and 
overall survival (OS). Toxicity was assessed according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. 
Tumor evaluation was performed at baseline and every 3 months until progression 
by physical examination in stage III patients and by CT scan according to RECIST 
version 1.1 in stage IV patients. 
Vaccine production 
Monocytes were enriched from leukapheresis products by plastic adherence of 
blood mononuclear cells or by counterflow centrifugation using Elutra-cell separator 
(Gambro BCT, Lakewood, CO) and single-use, functionally sealed disposable Elutra 
sets, as described before. 16 Monocytes were cultured in X-VIVO 15 medium (Lonza, 
Walkersville, USA) supplemented with 2% human serum (HS; Sanquin, 
Amsterdam, the Netherlands)  in the presence of IL-4 (500 U/ml), granulocyte 
macrophage colony-stimulating factor (800 U/ml) (both Cellgenix, Freiburg, 
Germany) and KLH (10 μg/ml, Calbiochem, Darmstadt, Germany). DCs were 
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matured with a cocktail of 10 ng/ml TNF-α, 5 ng/ml IL-1β, 15 ng/ml, IL-6 (all 
Cellgenix) and PGE2 (10 μg/ml, Pharmacia & Upjohn, Puurs, Belgium). 17 DCs were 
electroporated with mRNA encoding gp100 (Hautklinik, Erlangen, Germany or 
CureVac GmbH, Tübingen, Germany) or tyrosinase (eTheRNA, Brussels, Belgium 
or CureVac), as previously described. 18 Flow cytometry was used to characterize 
the phenotype of the ex vivo generated DCs. The following monoclonal antibodies 
or appropriate isotype controls were used: anti-HLA ABC-PE, anti-HLA DR-PE, 
anti-CD80-PE, anti-CD83-PE, anti-CD86-PE, anti-CD3-PE, anti-CD25-PE, anti-CD95-PE 
(all BD Biosciences, San Jose, CA), anti-CD14-PE (Sanquin Reagents, Amsterdam, 
the Netherlands), anti-HLA-DQ-PE, anti-CD20-PE (both Biolegend, San Diego, CA), 
and anti-CCR7-PE (Miltenyi Biotec, Bergisch-Gladbach, Germany). For intracellular 
staining, NKI/beteb (IgG2b; purified antibody) against gp100 and T311 (IgG2a; Cell 
Marque Corp., Rocklin, CA) against tyrosinase were used. Flow cytometry was 
done with FACSCalibur flow cytometer equipped with CellQuest software (BD 
Biosciences). Patients could only participate if the produced vaccines met the 
predefined phenotypic minimal release criteria of mature DCs used in clinical 
trials. 19 DCs were resuspended in NaCl 0.9% (B. Braun, Melsungen, Germany) with 
5% HS albumin (Sanquin) and administered both intradermally (maximum of 
10x106 cells in maximum 200 μl) and intravenously (maximum of 20x106 cells in 
maximum 1 ml). The DC products were manufactured and released for the clinical 
trial under a EU Good Manufacturing Practice (GMP) manufacturers license. 
KLH-specific proliferation 
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood 
by Ficoll-Paque density centrifugation, and stimulated with KLH (4 μg/2×105 
PBMCs) in X-VIVO with 2% HS. After 3 days, cells were incubated with 3H-thymidine 
for 8 hours and incorporation was measured with a β-counter. Experiments were 
performed in sextuplicate, non-specific proliferation upon stimulation with 
ovalbumin was used as control. Proliferative response to KLH is given as proliferation 
index (proliferation with KLH/proliferation without KLH).
Skin-test infiltrating lymphocyte culture analysis
Skin tests were performed within 2 weeks after each vaccination cycle as 
described previously. 20 Briefly, DCs electroporated with either gp100, tyrosinase 
or both antigens (maximum of 1x106 DCs) were injected intradermally in the skin 
of the back of patients at different sites, 4 cm apart from each other. After 48 
hours, punch biopsies (6 mm) were taken. Half of the biopsy was stored and half 
manually cut and cultured for 2-4 weeks in RPMI-1640 containing 7% HS and IL-2 
(100 U/ml). 
 Skin-test infiltrating lymphocyte (SKIL) cultures and PBMCs from HLA-A*02:01 
positive patients were stained with tetrameric-MHC complexes containing the 
HLA-A*02:01-binding epitopes gp100:154-162, gp100:280-288, or tyrosinase:369-
377 as described before. 21 Tetrameric-MHC complexes recognizing HIV were used 
as correction for background binding. Tetramer positivity was defined as at least 
two-fold increase in the double positive population. In these HLA-A*02:01 positive 
patients, the production of Th1 (IFN-γ and IL-2) and Th2 (IL-5) cytokines was 
measured in supernatants after 16 hours of co-culture with different target cells. 
These target cells were T2 cells pulsed with gp100:154-162, gp100:280-288, or 
tyrosinase:369-377; BLM (a melanoma cell line expressing HLA-A*02:01 and no 
endogenous expression of gp100 and tyrosinase), transfected with control antigen 
G250, gp100 or tyrosinase; and an allogenic HLA-A*02:01-positive, gp100-positive, 
and tyrosinase-positive tumor cell line (Mel624). Cytokine analysis was performed 
by cytometric bead array (Th1/Th2 Cytokine CBA 1; BD Pharmingen, San Diego, 
CA or human Th1/Th2 FlowCytomix multiplex kit, eBioscience, Vienna, Austria), 
according to the manufacturer instructions. A positive functional T cell response 
was defined by specific production of Th1 cytokines and no Th2 cytokines.
 In HLA-A*02:01 negative patients, antigen recognition by SKILs was 
determined by using autologous EBV-transformed B (EBV-B) cells as described by 
van Nuffel and colleagues. 22 Autologous EBV-B cells were generated from PBMCs 
and electroporated with mRNA encoding full-length gp100 or tyrosinase (CureVac). 
For mRNA electroporation, EBV-B cells were washed twice in PBS and once in 
OptiMEM without phenol red. Twenty micrograms of mRNA were transferred to 
a 4 mm cuvette (Bio-Rad, Hercules, CA) and 10-20×106 cells were added in 200 μL 
OptiMEM and incubated for 3’ before being pulsed in a Genepulser Xcell (Bio-Rad) by 
an exponential decay pulse of 450 V, 150 μF. Immediately after electroporation, 
cells were transferred to warm (37⁰C) X-VIVO 15 without phenol red supplemented 
with 6% HS and left for at least 2 hours at 37⁰C, before further manipulation. EBV-B 
cells electroporated with CEA-mRNA were used as a negative control. mRNA-loaded 
EBV-B cells were co-cultured 1:1 with SKILs for 24 hours and after 24 hours antigen 
specificity was analyzed by flow cytometry by expression of the early activation 
markers CD69, CD107a and CD137 on CD8+ T cells. PMA-stimulated (5 μg/mL; 
Sigma-Aldrich, Saint Louis, MO) SKILs were used as a positive control. After 24 
hours of co-culture, cytokine production was measured in supernatants with a 
FlowCytomix Multiplex kit (Bender MedSystems GmbH, Vienna, Austria). 
Immunofluorescence staining 
Immunofluorescence staining was performed on 4 μm thick sections of frozen 
resection specimens of melanoma metastases. Heat-induced antigen retrieval 
was performed in 10mM citrate acid buffer (pH 6.0) by microwaving method for 
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5 minutes after boiling. Blocking was performed with 1% BSA in TBST for 10 minutes 
at room temperature. Samples were stained by Opal TSA Plus multiplex tissue 
staining kits (Perkin Elmer, Waltham, MA) according to the standard protocol 
provided. Slides were subsequently stained with rabbit anti-Granzyme B (IgG, 
Abcam, Cambridge, UK) labeled with Opal 690 fluorophore, mouse anti- HLA-DR 
(IgG2b, Thermo Fisher Scientific, Waltham, MA) labeled with Cyanine 3 fluorophore, 
mouse anti-CD45RO (IgG2a, Thermo Scientific) labeled with Opal 620, mouse 
anti-CD8 (IgG1, Dako, Heverlee, Belgium) labeled with Opal 570, rabbit anti-CD3 
(IgG, Thermo Scientific) labeled with Opal 520, mouse anti-Foxp3 (IgG1, eBioscience) 
labeled with Opal 540; and a cocktail to identify tumor cells (melanoma mix) 
consisting of mouse anti-HMB45 (IgG1, Dako), mouse anti-Mart-1 (IgG1, Thermo 
Immunologic, Duiven, The Netherlands), mouse anti-Tyrosinase (IgG2a, Monosan, 
Uden, The Netherlands) and rabbit anti-SOX-10 (IgG, Cell Marque, Rocklin, CA) 
labeled with Opal 650. BrightVision poly-HRP-anti Ms/Rb/Rt IgG (Immunologic BV) 
was used for the secondary antibody incubations. Finally slides were counterstained 
with DAPI and mounted using Fluoromount-G (Southern Biotechnology Associates 
Inc, Birmigham, AL). Whole slide multispectral scan was performed using the 
Vectra slide scanner (version 2.0.7; PerkinElmer). Multispectral images were 
unmixed using spectral libraries build from images of single stained tissues for 
each reagent and unstained tissue using inform (version 2.1.1; PerkinElmer). 
Statistical analysis
A study sample of 22 stage III and 32 stage IV patients, who completed at least one 
DTH skin-test, was planned. With an anticipated 30% immunological response 
rate for the arm without cisplatin, we estimated that, a sample size of 27 patients 
per arm would give the study 80% power to detect an increase to 70% in the arm 
with cisplatin (two-sided Log-rank test, significance level alpha 0.05). Extra 
patients were included to reach a total of 54 immunologically evaluable patients, 
when patients did not complete at least one DTH. RFS (stage III patients), PFS 
(stage IV patients), and OS (all patients) were calculated from the date of apheresis 
to the date of recurrence, progression and death, using the Kaplan-Meier method. 
Statistical significance was evaluated using a log-rank test. Only patients who 
completed at least one DTH were analyzed. Statistical significant differences 
in baseline characteristics were evaluated using chi-square tests. Paired t-tests 
were performed to evaluate KLH responses before and after vaccination and 
 independent-samples t-tests were used to evaluate differences in increase in KLH 
proliferation. Ulceration was assumed absent if not reported in the pathology 
report. P values less than 0.05 were considered significant. SPSS version 20.0 
software (SPSS Inc, Chicago, IL) and Graphpad Prism 5.03 (GraphPad Software inc, 
San Diego, CA) were used for statistical analysis.
Results
Patient and vaccine characteristics
Between February 2011 and July 2014, 22 stage III and 38 stage IV melanoma 
patients were randomly assigned to receive either DC vaccination alone or DC 
vaccination combined with cisplatin 50 mg/m2. Six stage IV patients were not 
 immunologically evaluable and therefore excluded from analysis, since they did 
not complete at least one DTH skin-test; 4 patients showed progressive disease 
before or during the first cycle, and in 2 patients no acceptable vaccine could be 
produced (Supplementary Figure 1). In all other patients, the produced vaccines in 
both treatment groups met the predefined phenotypic release criteria of mature 
DCs used in clinical trials (Supplementary Figure 2A). Flow cytometry confirmed 
intracellular expression of both gp100 and tyrosinase, in both patient groups 
(Supplementary Figure 2B). 
 Patient characteristics of all immunologically evaluable patients are summarized 
in Table 1. No significant differences in baseline characteristics were found 
between patients treated with or without cisplatin. Overall in the stage III group, 
4 patients (18%) had stage IIIA, 8 (36%) had stage IIIB, and 10 (45%) had stage IIIC 
disease. A total of 10 stage III patients (45%) completed all 3 cycles of vaccinations; 
6 patients receiving cisplatin and 4 patients with DC vaccination alone. In 11 stage III 
patients (92%) who did not complete all 3 cycles, vaccinations were stopped 
due to progressive disease. The stage IV group included 24 patients (75%) with 
advanced cutaneous melanoma, 4 patients (13%) with an unknown primary, and 
4 patients (13%) with metastatic uveal melanoma. Only 3 stage IV patients (9%) 
completed 3 cycles of vaccinations, of whom 1 patient received the last two cycles 
after she underwent resection of cutaneous metastases and a limb perfusion due 
to localized progressive disease between cycles one and two. In all stage IV 
patients who did not complete all 3 cycles, vaccinations were stopped due to 
progressive disease. Median follow-up time from apheresis to patient death or 
censoring was 25.8 months (range 5.2-41.3 months) in stage III patients and 16.2 
months (range 3.7-34.1 months) in stage IV patients. 
Adverse events 
The safety analysis included all 54 patients who completed at least one cycle of 
vaccinations (Table 2). The 4 patients who did receive DCs, but did not complete at 
least one cycle, showed no striking features in their toxicity profile. Cisplatin was 
stopped because of adverse events in 3 patients (11%) in the combination treatment 
group; in one stage IV patient because of grade 3 heart failure due to cisplatin- 
hydration, in a stage III patient due to a persistent grade 2 tinnitus, and in another 
stage III patient on his request because of grade 2 nausea and fatigue. DC 
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vaccination was continued as monotherapy in all three patients. The dose of 
cisplatin was reduced in 1 patient (4%), because of grade 2 nausea. Adverse events 
leading to dose interruptions occurred in 2 patients (7%) treated with cisplatin; 
in one patient due to tinnitus and in the other patient due to thrombocytopenia. 
 Most common therapy-related adverse events of any grade occurring in the 
combination treatment group were nausea (67%), flu-like symptoms (63%), 
injection site reaction (37%), and fatigue (26%). In the group treated with DC 
vaccination monotherapy, the most frequent adverse events were flu-like 
symptoms (81%), injection site reaction (78%), nausea and vomiting (both 15%). 
Flu-like symptoms lasted usually less than 48 hours. One therapy-related grade 3 
adverse event (4%) and no grade 4 adverse events occurred in patients receiving 
the combination with cisplatin, while no grade 3-4 events were seen in patients 
treated with DC vaccination monotherapy.     
Immunological responses
DCs were loaded with the control antigen KLH, to test the capability to induce de 
novo immune response upon DC vaccination. PBMCs, collected before start of 
therapy and after consecutive vaccinations of the first cycle, were available for 53 
patients (98%) and analyzed for the occurrence of KLH-specific T cell responses. 
An increase in KLH-specific T cell proliferation was found in all patients and no 
significant difference in mean increase was found between both treatment 
groups (p=0.453; Figure 1). 
 PBMCs and SKILs, cultured from biopsies of DTH sites, of 31 HLA-A*02:01 
positive patients (57%) were screened for the presence of TAA-specific CD8+ T cells 
by tetrameric MHC-peptide complexes; 18 patients in the combination treatment 
group and 13 patients in the monotherapy group. Antigen-specific T cells were 
found in PBMCs of 3 patients (10%) and in SKILs of 17 patients (55%). Tetramer- 
positive CD8+ T cells were found in 59% of stage III patients and in 50% of stage IV 
patients tested. No significant differences were found between the combination 
treatment group and monotherapy group (Table 3). Furthermore, the biopsies of 50 
Table 2  Adverse events  
DC vaccination
(n=27)
DC vaccination + cisplatin 
(n=27)
P-value
Grade 1 Grade 2 Grade 1 Grade 2 Grade 3
Related to treatment*
Any eventa 22 (81%) 2 (7%) 18 (67%) 7 (26%) 1 (4%) 0.159
Most common adverse events
Injection site reaction 20 (74%) 1 (4%) 10 (37%) 0 0 0.008
Flu-like symptomsb 19 (70%) 3 (11%) 17 (63%) 0 0 0.092
Nausea 4 (15%) 0 15 (56%) 3 (11%) 0 <0.001
Vomiting 4 (15%) 0 1 (4%) 3 (11%) 0 0.091
Creatinine rise 2 (7%) 0 3 (11%) 0 0 0.639
Anorexia 1 (4%) 0 2 (7%) 0 0 0.552
Constipation 0 0 7 (26%) 0 0 0.005
Fatiguec 0 0 4 (15%) 3 (11%) 0 0.018
Tinnitus 0 0 3 (11%) 2 (7%) 0 0.064
Neuropathy 0 0 2 (7%) 0 0 0.150
*attributed by investigator
a  One patient in combination treatment group had therapy-related grade 3 decompensated heart failure.
b  Flu-like symptoms include fever, fatigue, chills, muscle aches, malaise, loss of appetite and headache.
c  Fatigue was mentioned separately when it lasted longer than other flu-like symptoms or when it was 
present without other flu-like symptoms.
Figure 1  KLH-specific T cell proliferation
KLH-specific T cell proliferation was measured before the start of therapy and after each vaccination of 
the first cycle in peripheral blood mononuclear cells of melanoma patients. The proliferative response to 
KLH is given as a proliferation index (proliferation with KLH/proliferation without KLH). A significant 
increase in KLH-specific T cell proliferation was seen in both patients treated with combination 
treatment, as well as patients treated with DC vaccination monotherapy. No significant difference in 
mean increase of KLH-specific T cell proliferation was found between patients treated with or without 
cisplatin. 
* p<0.001; ns = not significant 
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cytokines in response to relevant target cells in HLA-A*02:01 positive patients, and 
by using EBV-B cells in HLA-A*02:01 negative patients. A functional T cell response 
was found in 14 patients (28%); no difference were found between the two 
treatment groups (Table 3). Significantly more functional T cell responses were 
found in HLA-A*02:01 positive patients than in HLA-A*02:01 negative patients 
(40% versus 10%; p=0.02). A functional T cell response was seen in 41% of stage III 
patients and in 18% of stage IV patients (p=0.07).  
 Sequential tumor-biopsies were taken in one patient with a partial response 
on DC vaccination with cisplatin (Figure 2). This patient was HLA-A*02:01 negative 
and did not show a functional T cell response in the DTH-biopsies, but showed 
clear tumor necrosis and T cell infiltration in tumor-biopsies during treatment.
Clinical responses
Median RFS of stage III patients in the combination treatment group was not 
reached versus 10.9 months (95% confidence interval (CI), 1.5-20.3 months) in the 
monotherapy group (p=0.137; Figure 3A). The RFS rates in the combination treatment 
group and DC vaccination monotherapy group, were 64% and 36% at 1 year, and 
64% and 27% at 2 years. The median OS of stage III patients treated with cisplatin 
was not reached, as compared with 30.1 months in stage III patients without 
cisplatin (p=0.084; Figure 3B) 
 Median PFS of advanced melanoma patients in the combination treatment 
arm was 4.7 months (95% CI, 3.3-6.1 months), as compared to 3.0 months (95% CI, 
2.2-3.8 months) in the DC vaccination monotherapy group (p=0.10; Figure 3C). 
When excluding primary uveal melanoma patients (3 patients in the monotherapy 
group and 1 in the cisplatin group), median PFS was 5.4 months (95% CI, 4.4-6.3 
months) in the combination group versus 3.5 months (95% CI, 2.8-4.2 months) in 
the monotherapy group (p=0.121). Advanced melanoma patients treated with DC 
vaccination monotherapy had a significantly longer OS; median OS 19.0 months 
(95% CI, 1.7-36.2 months) versus 12.2 months (95% CI, 8.3-16.0 months) in patients in 
the combination treatment arm (p=0.026; Figure 3D). However, in comparison 
with the combination treatment group, significantly more patients with 
progressive disease in the monotherapy group subsequently received treatment 
with ipilimumab (69% versus 33%; p=0.049) or with anti-PD1 (31% versus 0%; 
p=0.018). 
Table 3  Tumor-associated antigen-specific immunological responses  
DC vaccination DC vaccination  
+ cisplatin
P value
Tetramer-specific CD8+ T cells in PBMCsa
    No
    Yes
n=13
12 (92%)
1 (8%)
n=18
16 (89%)
2 (11%)
0.474
Tetramer-positive CD8+ T cells in SKILsa
    No
    Recognizing 1 antigen
    Recognizing 2 antigens
n=13
5 (38%)
2 (15%)
6 (46%)
n=18
9 (50%)
5 (28%)
4 (22%)
0.354
Functional T cells in SKILsb
    No
    Recognizing 1 antigen
    Recognizing 2 antigens
n=25
19 (76%)
5 (20%)
1 (4%)
n=25
17 (68%)
8 (32%)
0
0.529
TAA-specific T cells in SKILsc
    No
    Yes
n=27
18 (67%)
9 (33%)
n=27
15 (56%)
12 (44%)
0.402
a  TAA-specific CD8+ T cells by tetrameric MHC-peptide complexes in HLA-A*02:01 positive patients.
b  Production of Th1 cytokines , and no Th2 cytokines, in response to relevant target cells in HLA-A*02:01 
positive patients, and to EBV-B cells electroporated with mRNA encoding full-length gp100/tyrosinase 
HLA-A*02:01 negative patients. No material was available for testing in 2 patients of each treatment 
group.
c  Presence of tetramer-specific CD8+ T cells and/or functional T cells in SKILs.
Figure 2  T cell infiltration in metastases 
Multispectral images of cutaneous metastases were made using the Vectra slide scanner at the start of 
treatment and during vaccinations in a patient with a partial response to DC vaccination in combination 
with cisplatin. Panel A includes a biopsy at the start of treatment and the overview image shows 
extensive melanoma cells with groups of CD3+ cells. When zoomed in (middle image), it reveals that 
CD8+ T cells and granzyme B, a serine protease most commonly found in granules of cytotoxic T cells 
and natural killer cells that mediates apoptosis in target cells, were already present at the start of 
treatment. Panel B shows an image of part of a clinically responding metastasis (another metastasis 
than the one in panel A) after the second cycle of vaccinations and cisplatin; only few melanoma cells 
were detected while an extensive T cell infiltrate was found, including CD8+ T cells and CD45RO+ cells, 
which is located on memory T cells.
A B
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Discussion
In this randomized phase 2 study, we showed that combining autologous 
monocyte- derived DC vaccination with cisplatin (50 mg/m2) is feasible and safe. 
Viable DCs, which met the previously determined minimal release criteria, could 
be produced in 97% of patients. 19 The safety profile of the combination treatment 
showed no unexpected safety concerns. Adverse events leading to discontinuation, 
treatment interruption (7%) or dose reduction (4%) happened only in a minority of 
patients in the combination treatment group. As expected, grade 1-2 local injection 
site reactions and flu-like symptoms were common adverse events in both 
treatment groups, but occurred less in the combination treatment group. These 
side effects might have been suppressed by dexamethasone, which was given as 
an antiemetic in patients receiving cisplatin.    
 DC vaccines were able to induce de novo immune responses in both treatment 
groups, as all tested patients showed a cellular response against the control 
antigen KLH. Tetramer-positive CD8+ SKILs recognizing TAA were seen in a 
majority of patients (55%). Additionally, 30% of patients showed functional 
TAA-specific T cells. A functional T cell response was found in more stage III 
patients than stage IV patients, which is comparable with an earlier trial using 
mRNA-electroporated DCs. 2 Significantly more HLA-A*02:01 positive than 
HLA-A*02:01 negative patients  showed a functional T cell response. No biological 
reasons for this difference are expected, while electroporation with synthetic 
mRNA results in endogenous synthesis of a complete TAA independent of 
HLA-type. A possible explanation for this difference might be that the EBV-based 
assay, used in HLA-A*02:01 negative patients, was less specific in our hands than 
described by Van Nuffel and colleagues. 22 Therefore, the amount of patients with 
a functional T cell response might be underestimated in the HLA-A2 negative 
group. 
 The combination of DC vaccination and cisplatin showed no significant 
increase in T cell responses in stage III and IV melanoma patients, which may 
have several reasons. Firstly, it is possible that the immunomodulatory effects of 
cisplatin are not strong enough in vivo to induce a significant difference in the 
number of T cell responses. Unfortunately, a clear statement about the in vivo 
effect of cisplatin on the tumor microenvironment in stage IV patients cannot be 
given, since consecutive tumor biopsies were performed in only one patient. To 
further explore the in vivo effects of cisplatin, we will further analyze differences 
in PBMCs between patients treated with or without cisplatin, in particular 
focused on circulating MDSCs. Secondly, dexamethasone could have had a 
negative effect on DC vaccination in the combination treatment group, as cortico-
steroids give a decrease in circulating T cell precursors, IL-2 production, and an 
impaired ability to respond to IL-2. 23, 24 Although the time between the last gift 
of dexamethasone and the DTH skin test was at least 1 week, there could still 
have been a negative influence on the DTH skin test, since the biological half-life 
of dexamethasone is 36-72 hours. 24 For this reason, the number of (functional) 
T cell responses in the combination treatment group might have been 
underestimated. In contrast to our study, Welters and colleagues found that 
chemotherapy (6 cycles carboplatin-paclitaxel every  3 weeks) resulted in vigorous 
Figure 3  Survival curves in stage III and IV melanoma patients
Panels A and B show the Kaplan-Meier curves for recurrence-free survival and overall survival in stage 
III melanoma patients, respectively. A trend was seen for a better overall survival in patients treated 
with dendritic cell (DC) vaccination and cisplatin as compared to patients receiving DC vaccination 
monotherapy, but this difference is not significant. Panels C and D show the Kaplan-Meier curves for 
progression-free survival and overall survival in stage IV melanoma patients, respectively. No 
differences were found in progression-free survival between both treatment-groups, but a significant 
longer overall survival was observed in the DC vaccination monotherapy group than in the group with 
cisplatin (hazard ratio for death, 0.38; 95% CI, 0.16-0.92; p=0.031).
A
C
B
D
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vaccine-induced T cell responses in advanced cervical cancer patients when a 
single dose of HPV16-SLP vaccine was given 2 weeks after the second cycle of 
chemotherapy. 25 Of course, there are differences in tumor type, chemotherapy, 
and type of vaccinations, but the most important difference might be the time 
interval between chemotherapy and vaccinations, providing another potential 
reason for why we did not find a difference in T cell responses. In our study, 
vaccinations and chemotherapy were both initiated in the first cycle, while their 
study showed that the effect of chemotherapy on decreasing circulating myeloid 
cells was most pronounced starting 2 weeks after the second cycle of chemotherapy, 
resulting in an optimal immunological window for vaccination. 
 A trend for a better OS is observed in stage III patients treated with DC 
vaccination and cisplatin compared to patients treated with DC vaccination 
monotherapy, but the study was not designed to draw definite conclusions on 
clinical outcome. Furthermore, stage III patients with DC vaccination monotherapy 
performed worse in this study as compared to an earlier study describing 
78 patients treated with monocyte-derived DC vaccination. 5 The small number 
of patients in this study might have caused discrepancies in prognostic patient 
characteristics between both studies, despite corresponding inclusion criteria. 
A limitation of this study is that stage III patients were screened for distant 
metastases with imaging studies before their RLND, but not before start of DC 
vaccinations, which might have resulted in some patients having recurrent 
disease before the start of vaccinations, and therefore influencing survival rates. 
In stage IV patients, no difference in PFS was found between both treatment 
groups, while OS was significantly longer in patients treated with DC vaccination 
monotherapy. This can probably be explained by the fact that in this treatment 
arm significantly more patients received ipilimumab and/or anti-PD-1 after 
progression upon DC vaccination. 
 This trial was initiated before checkpoint inhibitors were available, but today 
combining DC vaccination with checkpoint inhibitors might be preferred over 
the combination with chemotherapy. 26 Proliferation and effector functions of 
tumor-specific T cells induced by DC vaccination could be intensified by blocking 
immune checkpoints with ipilimumab or anti-PD-1. 27, 28 A recent phase 2 trial 
with autologous monocyte-derived DCs combined with ipilimumab showed 
tolerability and an encouraging objective response rate (38%) in heavily 
pre-treated advanced melanoma patients. 29 Further clinical trials are warranted 
to confirm these results. 
 In conclusion, the combination of autologous monocyte-derived DC 
vaccination and cisplatin in stage III and IV melanoma patients is feasible and 
safe, but does not result in more tumor-specific T cell responses, when compared 
to DC vaccination monotherapy. Together with the data on clinical outcome, these 
results do not appear to justify the use of DC vaccination combined with cisplatin in 
this setting. Combining DC vaccination with checkpoint inhibitors will probably 
be the main focus of future combination treatment trials with DC vaccination.
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Supplementary Figure 2  Vaccine characteristics
No significant differences were found between patients treated with DC vaccination alone or the 
combination of DC vaccination with cisplatin with regard to the phenotype (A) or intracellular 
expression of both gp100 and tyrosinase (B) of the generated DCs of the immunologically evaluable 
patients.
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Abstract
Background: Ipilimumab has proven to be effective in metastatic melanoma 
patients. The purpose of this study was to determine the efficacy of ipilimumab in 
advanced melanoma patients who showed progressive disease upon experimental 
dendritic cell (DC) vaccination.
Methods: Retrospective analysis of 48 stage IV melanoma patients treated with 
ipilimumab after progression upon DC vaccination earlier in their treatment. 
DC vaccination was given either as adjuvant treatment for stage III disease (n=18) 
or for stage IV disease (n=30). Ipilimumab (3 mg/kg) was administered every 
3 weeks for up to 4 cycles. 
Results: Median time between progression upon DC vaccination and first gift of 
ipilimumab was 5.4 months. Progression-free survival (PFS) rates for patients that 
received ipilimumab after adjuvant DC vaccination, and patients that received DC 
vaccination for stage IV melanoma, were 35% and 7% at 1 year and 35% and 3% at 
2 years, while the median PFS was 2.9 months and 3.1 months, respectively. 
Median overall survival of patients pre-treated with adjuvant DC vaccination for 
stage III melanoma was not reached versus 8.0 months (95% CI, 5.2-10.9) in the 
group pre-treated with DC vaccination for stage IV disease (HR of death, 0.36; 
p=0.017). Grade 3 immune-related adverse events occurred in 19% of patients and 
one death (2%) was related to ipilimumab.
Conclusions: Clinical responses to ipilimumab were found in a considerable 
number of advanced melanoma patients with progression after adjuvant DC 
vaccination for stage III disease, while the effect was very limited in patients who 
showed progression after DC vaccination for stage IV disease.
Introduction
Melanoma is the most deadly form of skin cancer. 1 Before 2011, systemic treatment 
for advanced melanoma consisted only out of chemotherapy (typically dacarbazine) 
and, in some countries interleukin-2 (IL-2), but both options have a minimal effect 
on survival. 2 However, since 2011, multiple new drugs have been approved by the 
Food and Drug Administration (FDA) and European Medicines Agency (EMA). 
These new therapeutics include the checkpoint inhibitors ipilimumab, nivolumab, 
and pembrolizumab, and the targeted agents vemurafenib, cobimetinib, dabrafenib 
and trametinib. 3-9 Furthermore, multiple other treatments, amongst which 
dendritic cell (DC) vaccination, are still under investigation. 10 With the growing 
field of treatment options for melanoma, it is of vital importance that patients 
receive a personalized treatment-schedule, in which action-mechanisms and 
 toxicity-profiles are considered.
 Over the past years, we have treated stage III and stage IV melanoma patients 
with DC vaccination in different trials. 11-13 DCs are the most efficient antigen- 
presenting cells of the immune system due to their capacity to activate and prime 
naïve T cells, and may therefore play a vital role in anticancer immunotherapy. 
DCs can be isolated directly from patient’s blood, or differentiated  ex vivo 
from precursor cells, activated, loaded with tumor antigens, and then injected 
into patients. 14, 15 Although tumor-specific immune responses were found in stage 
IV melanoma patients treated with DC vaccination monotherapy, long-lasting 
clinical responses were rare. 13, 14, 16 Compared to patients with stage IV disease, 
tumor-specific immune responses were found in a higher percentage of stage III 
melanoma patients receiving DC vaccination, and in a retrospective analysis 
a significant increase in overall survival (OS) was found compared to matched 
controls receiving only surgery. 11 However, despite the presence of tumor- 
specific T cells after DC vaccination, a portion of stage III patients developed 
recurrent disease. Different immune-escape mechanisms, like immuno-
suppressive cytokines, regulatory T cells and myeloid derived suppressor cells 
(MDSCs) in the tumor micro environment, may play a role in the occurrence of 
recurrent or progressive disease despite the presence of tumor-specific CD8+ T 
cells. 17, 18 Furthermore, immune checkpoint molecules that down-regulate 
pathways of T cell activation, like cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) and programmed death 1 (PD-1) may hamper potent tumor eradication 
by activated T cells. 3, 6 Ipilimumab, a fully human monoclonal antibody that 
blocks CTLA-4, has proven to be effective in metastatic melanoma. Pooled analysis 
of phase 2 and 3 trials recently showed a median OS of 9.5 months and a plateau 
at 21% in the survival curve beginning approximately 3 years after start 
of ipilimumab. 19 A considerable portion of patients treated with ipilimumab is 
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affected by immune-related adverse events, but most are reversible when treated 
appropriately. 20 
 Based on their mechanism of action, DC vaccination and ipilimumab might 
be complementary to each other, either when given concomitantly, or when 
ipilimumab is given to patients as a subsequent treatment after progression on 
DC vaccination. These patients may have developed a tumor-specific T cell 
response on DC vaccination which was not strong enough for disease control, 
because of the immunosuppressive mechanisms mentioned before, but which 
could be enhanced by ipilimumab. Pierret and colleagues were the first to suggest 
a potential correlation between prior DC vaccination and clinical outcome in 
advanced melanoma patients treated with ipilimumab in a retrospective analysis 
of a small patient cohort. 21 Yuan and colleagues determined the effect of 
ipilimumab on antigen-specific responses following DNA or protein vaccination 
in 3 melanoma patients. Their patients generated weak to no antigen-specific 
CD4+ or CD8+ T cell responses following vaccination, but they experienced a clear 
antigen-specific T cell response after ipilimumab treatment, indicating that 
ipilimumab might have enhanced T cells induced by vaccination. 22 
 The aim of this retrospective study was to explore the clinical effect of 
ipilimumab in advanced melanoma patients with progressive disease after DC 
vaccination.
Materials and methods
Patient characteristics
We retrospectively analyzed patients who received ipilimumab for recurrent or 
progressive disease after pre-treatment in our DC vaccination trials. Ipilimumab 
was given between October 2008 and February 2015 and these patients were 
treated in various DC vaccination studies at our institute between February 2002 
and September 2014; either as adjuvant therapy within 2 months after radical 
lymph node dissection in case of  stage III melanoma patients, or for patients with 
stage IV (advanced) melanoma. Patients treated with ipilimumab for metastatic 
uveal melanoma were excluded from analysis. All patients treated with DC 
vaccination followed by ipilimumab at some point in their course of disease, were 
considered to be eligible for analysis. One patient was treated with four cycles of 
10 mg/kg ipilimumab every 3 weeks, followed by 10 mg/kg every 12 weeks as 
maintenance therapy. All other patients received four cycles of 3 mg/kg 
ipilimumab every 3 weeks, unless progression or severe side-effects occurred. 
Patients were staged according to the American Joint Committee on Cancer 2009 
criteria. 23 All DC vaccination studies were approved by the appropriate Medical 
Ethical Review Board and written informed consent for these trials was obtained 
from all patients.
Dendritic cell vaccination
Patients were treated with either monocyte-derived autologous DCs or naturally 
circulating DCs loaded with tumor-associated antigen (TAA) of gp100 and tyrosinase 
according to a schedule of 3 biweekly vaccinations. DCs were pulsed with two 
gp100-derived peptides (gp100:154-162 and gp100:280-288) and a tyrosinase- 
derived peptide (tyrosinase:369-377) or electroporated with mRNA encoding 
gp100 or tyrosinase, as described before. 24 Patients received 2 subsequent cycles 
of vaccinations at 6-month intervals in absence of recurrent or progressive 
disease. For the exact details of the vaccination protocols we refer to these 
individual studies (NCT02285413). 13, 16, 25-29 
 A delayed-type hypersensitivity (DTH) skin-test was performed within 2 weeks 
after each vaccination cycle as described previously. 12 Briefly, DC loaded with 
either gp100, tyrosinase or both antigens were injected intradermally in the skin 
of the back of patients at different sites, and after 48 hours, punch biopsies (6 mm) 
were taken. Skin infiltrating lymphocytes (SKILs) were analyzed for antigen- 
specific T cells by staining them with tetrameric-MHC complexes containing the 
gp100 and tyrosinase epitopes (HLA-A*02:01  positive patients) and TAA-specific 
functional responses by specific production of T helper (Th)1 cytokines and no Th2 
cytokines to TAA, as described before. 12
Response evaluation and toxicity
Patients underwent clinical evaluation at baseline and prior to each ipilimumab 
infusion. Furthermore, during the treatment with ipilimumab, radiological 
evaluations (CT or PET/CT scanning) were performed at baseline and week 12, and 
during follow-up around every 3 months or when disease progression was 
clinically suspected. This interval could be prolonged in individual cases with a 
durable response. Responses were scored by Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1.1. Progression-free survival (PFS; defined as the time 
from first cycle of ipilimumab to documented disease progression according to 
RECIST or death from any cause), OS (defined as the time from first cycle of 
ipilimumab to death from any cause), and the best objective response rate were 
analyzed.
 Safety evaluations were performed in all patients and consisted of immune- 
related adverse events; they were scored using the National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.02. Serious 
adverse events were determined as grade 3 or 4. Patients were treated for 
immune-related adverse events according to local guidelines.
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Statistical analysis
Survival was calculated from the start of ipilimumab to the date of progression 
(PFS) or death (OS) using the Kaplan-Meier method. Statistical significance was 
evaluated using a log-rank test. Cox proportional-hazard models were used to 
perform univariate and multivariate analysis of hazard ratios (HR). Multivariate 
survival analysis was applied to the significant variables of the univariate 
analysis. A Pearson correlation coefficient (r) was calculated to measure the 
relationship between the PFS on DC vaccination and the PFS on ipilimumab. 
P-values less than 0.05 were considered significant. SPSS version 22 software (SPSS 
Inc, Chicago, IL) and Graphpad Prism 5.03 (GraphPad Software inc, San Diego, CA) 
were used for statistical analysis. 
Results
Patients and treatment
Among 48 melanoma patients who progressed after DC vaccination included in 
this study, 18 patients were treated with adjuvant DC vaccination after radical 
lymph node dissection for stage III melanoma and 30 patients received DC 
vaccination for stage IV melanoma. Patient characteristics are shown in Table 1. 
Median PFS of DC vaccination was 14.0 months for stage III patients and 4.0 
months for patients with stage IV disease. Included among these patients were 4 
patients (8%) with M1a disease, 10 patients (21%) with M1b disease, and 34 patients 
(71%) had M1c disease at the start of ipilimumab. The median time between 
progressive disease on DC vaccination and the first cycle of ipilimumab was 5.4 
months for the whole study population. Half of the stage III patients (n=9) 
previously treated with adjuvant DC vaccination received ipilimumab as a first 
line treatment for advanced melanoma, partly because initially ipilimumab was 
not yet registered as first line treatment. In the group treated with DC vaccination 
for stage IV melanoma, ipilimumab was given as second (47%), third (50%) or 
fourth (3%) line of systemic treatment. A total of 34 patients (71%) completed all 4 
cycles of ipilimumab. The most frequent reason for discontinuation of ipilimumab 
was disease progression (62%). 
Clinical efficacy of ipilimumab after progression on DC vaccination
Patients were followed for up to 84.1 months after start of ipilimumab, with a 
median follow-up time until death or censoring of 9.2 months. The median PFS of 
ipilimumab in all patients was 3.1 months (95% confidence interval (CI), 2.4-3.7) 
and it was comparable in stage III patients pre-treated with adjuvant DC vaccination 
and patients who received prior DC vaccination for stage IV disease (2.9 months 
Table 1  Patient characteristics
DC vaccination  
for stage III melanoma 
(n=18)
DC vaccination  
for stage IV melanoma 
(n=30)
Age (years)
Mean (range) 53,1 (24-69) 55,4 (29-80)
Sex
Male
Female
15 (83%)
3 (17%)
20 (67%)
10 (33%)
Metastasis stage
M1a
M1b
M1c
3 (17%)
3 (17%)
12 (67%)
1 (3%)
7 (23%)
22 (73%)
Lactate dehydrogenase 
≤ULN
>ULN
13 (72%)
5 (28%)
20 (67%)
10 (33%)
Brain metastases
Yes
No
Unknown
4 (22%)
13 (72%)
1 (6%)
5 (17%)
16 (53%)
9 (30%)
BRAF status
V600 mutation
No V600 mutation
Unknown
10 (56%)
3 (27%)
5 (28%)
12 (40%)
14 (47%)
4 (13%)
Ipilimumab, line of  
treatment for metastatic disease
First
Second
Third
Fourth 
9 (50%)
7 (39%)
2 (11%)
0
0
14 (47%)
15 (50%)
1 (3%)
Number of cycles of  
ipilimumab
1 cycle
2 cycles
3 cycles
4 cycles
More
1 (6%)a
5 (28%)
0
11 (61%)
1 (6%)
2 (7%)
3 (10%)
3 (10%)
22 (73%)
0
Systemic treatment after progressive 
disease on ipilimumab
None
Chemotherapy 
Targeted therapy
Anti-PD-1
Other immunotherapy
7 (39%)
1 (6%)
4 (22%)
5 (28%)
1 (6%)
16 (53%)
4 (13%)
8 (27%)
4 (13%)
1 (3%)
Baseline characteristics were scored at the time of start of ipilimumab.
a  Patient has an ongoing partial response on 1 cycle ipilimumab which was stopped due to toxicity.
Abbreviations: DC, dendritic cell; n.a., not applicable; PD-1, programmed cell death 1; ULN, upper limit of 
normal
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versus 3.1 months). The PFS rates for ipilimumab in the group pre-treated with 
adjuvant DC vaccination for stage III disease, and the group pre-treated with DC 
vaccination for stage IV melanoma, were 35% and 7% at 1 year and 35% and 3% at 
2 years (Figure 1A; p=0.036), indicating more durable clinical responses in the 
adjuvant DC vaccination group. The individual treatment-schedules including 
the PFS of DC vaccination and ipilimumab of each patient is shown in Figure 2. 
No correlation could be found between the PFS of DC vaccination and the PFS 
of ipilimumab in the whole study population (r=0.077; p=0.602). 
 The median OS since start of ipilimumab of the whole study population was 
11.4 months (95% CI, 6.1-16.7). Four baseline characteristics correlated with OS in 
an univariate Cox proportional-hazards analysis: line of systemic treatment of 
ipilimumab, baseline serum lactate dehydrogenase (LDH), brain metastases 
before start of ipilimumab, and the stage of disease in which DC vaccination was 
administered (Table 2). The line of systemic treatment of ipilimumab, baseline 
LDH, and brain metastases before start of ipilimumab remained to correlate with 
OS in a multivariate Cox proportional-hazards model (all p<0.01).  Thirty-three 
patients with normal baseline serum LDH at the start of ipilimumab showed a 
significant longer OS than 15 patients with LDH levels above the upper limit of 
normal; median OS 16.3 months (95% CI, 10.1-22.6) versus 3.3 months (95% CI, 
2.2-4.3; p<0.001). Furthermore, the median OS of ipilimumab in 9 patients with 
Figure 1  Progression-free survival and overall survival of ipilimumab treatment
Kaplan-Meier curves for progression-free and overall survival of ipilimumab treatment in stage IV 
patients pre-treated with either adjuvant dendritic cell (DC) vaccination for stage III melanoma or with 
DC vaccination for stage IV melanoma. Survival was calculated from start of ipilimumab to the date of 
disease progression (Panel A) or death (Panel B). Patients pre-treated with adjuvant DC vaccination 
showed a significantly better progression-free survival and overall survival compared to patients 
treated with DC vaccination for stage IV melanoma.
Figure 2  Survival and treatment since start dendritic cell vaccination
Swimmers plot illustrating the progression-free survival of dendritic cell vaccination and ipilimumab, 
and the different treatments before and after ipilimumab of every individual patient. Progression-free 
survival of ipilimumab is independent of the progression-free survival of dendritic cell vaccination. 
 Patient alive at last follow-up
*Ipilimumab was started before progression on vemurafenib. 
Abbreviations: DC, dendritic cell; PD-1, programmed cell death 1; TIL, tumor-infiltrating lymphocytes
A
B
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brain metastases before start of ipilimumab was only 3.8 months (95% CI, 3.4-4.2) 
compared to 19.1 months (95% CI, 8.3-29.9) in 29 patients without brain metastases 
(HR 7.45; 95% CI 2.46-22.61; p<0.001). Eight of the patients with brain metastases 
were treated with radiotherapy and/or surgery before or during ipilimumab 
treatment. In addition, a trend was observed for the stage of disease in which DC 
vaccination was administered, to be a predictor of OS in the multivariate survival 
analysis, favouring adjuvant DC vaccination for stage III disease (HR 0.33; 95% CI, 
0.10-1.09; p=0.069). Median OS of patients pre-treated with DC vaccination for 
stage III melanoma was not reached, as compared to 8.0 months (95% CI, 5.2-10.9) 
in the group pre-treated with DC vaccination for stage IV disease. The OS rates for 
ipilimumab in the group pre-treated with DC vaccination for stage III disease, and 
the group pre-treated with DC vaccination for stage IV melanoma, were 64% and 
36% at 1 year and 53% and 21% at 2 years (Figure 1B). 
 The disease control rate (the proportion of patients with a partial response, 
complete response, or stable disease) of the whole study population was 35%. The 
group pre-treated with adjuvant DC vaccination for stage III disease had a best 
objective response rate of 22% (3 complete responses and 1 partial response) and a 
disease control rate of 44% on ipilimumab. The four patients with an objective 
response showed an ongoing PFS ranging from 10.5 to 84.1 months. In the group 
pre-treated with DC vaccination for stage IV melanoma, the best objective 
response rate was 10% (all partial responses) and the disease control rate was 
30%. All stage IV patients with a partial response progressed within 2 years, 
suggesting a small chance of durable responses in this group of patients.
Effect tumor-specific T cell responses by DC vaccination on 
ipilimumab treatment
During the DC vaccination trials, DTH skin-test biopsies were taken after each 
cycle of vaccinations. Lymphocytes out of these biopsies (SKILs) of 31 HLA-A*02:01 
positive patients were analyzed for antigen-specific T cells by staining with 
tetrameric-MHC complexes containing the gp100 and tyrosinase epitopes. 
Furthermore, TAA specific functional responses by specific production of T-helper 
(Th)1 cytokines and no Th2 cytokines were measured in all patients. For the whole 
study population, tetramer-positive T cells against one or more epitopes, were 
found in 18 patients (58%) and a functional T cell response was seen in 38% of 
patients. Patients treated with adjuvant DC vaccination for stage III melanoma 
showed significantly more tumor-specific T cell responses than patients treated 
with DC vaccination for stage IV disease, 72% versus 33% (p=0.009). However, no 
significant difference in OS since start of ipilimumab was found between patients, 
with or without, tumor-specific T cells in DTH skin-test biopsy sites; median OS 
11.5 months versus 8.1 months (p=0.476) for the whole study population. 
Additionally, no difference was found when only the patients pre-treated with 
adjuvant DC vaccination for stage III disease were analyzed (p=0.883).      
Immune-related adverse events of ipilimumab
Immune-related adverse events of any grade occurred in 58% of the patients 
(Table 3). The most common immune-related adverse events were dermatitis 
(29%) and diarrhoea/colitis (27%). The incidence of immune-related grade 3 
adverse events was 19%, while no grade 4 events were reported. Immune-related 
adverse events of any grade that led to discontinuation of ipilimumab occurred in 
Table 2  Univariate analysis of overall survival
n Median OS 
(months)
HR 95% CI P value
 Sex
Male
Female
35
13
8.1
12.8
1
0.881 0.41-1.92 0.750
Age in categories, years
<41
41-50
51-60
≥61
5
11
14
18
8.0
6.4
11.4
9.7
1
1.366
1.151
1.311
0.36-5.19
0.29-4.52
0.37-4.63
0.647
0.841
0.674
Metastasis stage
M1a
M1b
M1c
4
10
34
17.3
19.1
8.0
1
0.644
1.593
0.12-3.36
0.37-6.78
0.602
0.529
Lactate dehydrogenase 
≤ULN
>ULN
33
15
16.3
3.3
1
3.561 1.75-7.23 <0.001
Brain metastases
No
Yes
Unknown
29
9
10
19.1
3.8
8.7
1
4.321
2.797
1.61-11.62
1.22-6.41
0.004
0.015
Ipilimumab, line of treatment for 
metastatic disease
First
Second
Third or fourth
9
21
18
17.3
24.7
4.7
1
1.217
4.323
0.33-4.43
1.26-14.78
0.766
0.020
Stage DC vaccination
Stage IV
Stage III
30
18
8.0
Not reached
1
0.36 0.16-0.83 0.017
Univariate analysis of relevant baseline co-variables that might correlate with overall survival following 
ipilimumab treatment.
Abbreviations: CI, confidence interval; DC, dendritic cell; HR, hazard ratio; OS, overall survival, ULN, 
upper limit of normal
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10% of the patients. One death due to the toxic effects of ipilimumab was reported 
(bowel perforation caused by inflammatory colitis). 
Discussion
This retrospective study showed that ipilimumab resulted in effective clinical 
responses in metastatic melanoma patients who presented with advanced 
melanoma after previous adjuvant DC vaccination for stage III disease, while 
ipilimumab had only limited effect on survival in patients with progressive 
disease on DC vaccination for stage IV disease. The characteristics of the study 
participants were comparable with those of the landmark studies with 
ipilimumab, especially with regard to M-stage, LDH level and brain metastases. 3, 
4, 30 More than 70% of the patients had M1c disease and more than 30% had an 
elevated LDH, both of which are associated with poor survival. 31, 32 The results of 
this study support the recent findings about the unlikely long-term benefit of 
ipilimumab treatment for patients with raised baseline serum LDH levels. 33, 34
 Ipilimumab-treated advanced melanoma patients pre-treated with adjuvant 
DC vaccination for stage III disease showed significantly better PFS and OS rates 
as compared to ipilimumab-treated patients who progressed on DC vaccination 
for stage IV melanoma. This might partly be caused by the difference in systemic 
line of treatment of ipilimumab between both groups. Theoretically, this 
difference might also be explained by a more effective induction of TAA-specific 
T cells in patients receiving adjuvant DC vaccination. However, no difference in 
survival was found between patients with or without TAA-specific T cells after 
DC vaccination. The time between induction of these T cells and start of 
ipilimumab might be too long in some patients to benefit from a potential synergy, 
or the sample size of this study was too small to detect a significant difference. 
Another reason might be that strengthened T cell responses by ipilimumab were 
not captured in our method of immunomonitoring. Patients treated with 
ipilimumab after adjuvant DC vaccination for stage III melanoma showed a best 
objective response rate of 22%, an estimated 64% of patients were still alive at 1 
year, and an estimated 35% of patients were free of progression at 2 years after 
start of ipilimumab. Despite the small number of patients included in this 
retrospective analysis, these survival rates are promising in light of the results of 
phase 3 trials with ipilimumab, since these studies showed one-year OS rates of 
45.6-47.3%, and two-year PFS rates of around 12%. 3, 4 A retrospective study with 
stage III melanoma patients showed a significantly better OS in patients treated 
with DC vaccination compared to matched controls who only received surgery. 11 
Of course, these results have to be confirmed in a prospective randomized clinical 
trial and compared to the results of trials with adjuvant ipilimumab 35 and 
anti-PD-1 mAb (NCT02388906, NCT02362594). However, the fact that patients 
with recurrent disease on adjuvant DC vaccination still respond to ipilimumab 
might be an argument to choose for adjuvant DC vaccination over adjuvant 
treatment with ipilimumab when comparable clinical outcomes are found in 
these adjuvant trials, since it increases the treatment-options in case of stage IV 
disease after adjuvant treatment for stage III disease.
 In contrast to patients pre-treated with adjuvant DC vaccination for stage III 
melanoma, patients who showed progressive disease after DC vaccination for 
stage IV disease responded very poorly to ipilimumab treatment. Hodi and 
colleagues found a long-term OS in 20% of pre-treated melanoma patients 3, while 
all patients pre-treated with DC vaccination for stage IV disease showed 
progressive disease within 2 years after start of ipilimumab. In theory, this 
difference might be explained by a selection of patients who are less prone to 
immunotherapy, since only patients with progressive disease after DC vaccination 
were included in this study, whereas the patients in the study of Hodi were 
predominantly pre-treated with standard of care chemotherapy. 3 However, 
long-lasting clinical responses were rare in trials with monotherapy DC 
vaccination in stage IV melanoma patient 14, 25, which makes it unlikely that this 
selection bias is the sole cause of the limited effect of ipilimumab in these patients. 
Furthermore, the poor response to ipilimumab may be caused by the fact that 
Table 3  Immune-related adverse events ipilimumab
Any grade Grade 1 Grade 2 Grade 3 Grade 5
Any immune-related adverse 
event
28 (58.3%) 17 (35.4%) 4 (8.3%) 9 (18.8%) 1 (2.1%)
  Dermatitis 14 (29.2%) 13 (27.1%) 0 1 (2.1%) 0
  Diarrhoea /colitis 13 (27.1%) 5 (10.4%) 2 (4.2%) 5 (10.4%) 1 (2.1%)
  Uveitis 3 (6.3%) 0 1 (2.1%) 2 (4.2%) 0
  Conjunctivitis 2 (4.2%) 2 (4.2%) 0 0 0
  Hypophysitis 1 (2.1%) 0 0 1 (2.1%) 0
  Pneumonitis 1 (2.1%) 0 1 (2.1%) 0 0
  Vitiligo 1 (2.1%) 1 (2.1%) 0 0 0
Treatment-related adverse event 
leading to discontinuation
5 (10.4%) 0 1 (2.1%) 3 (6.3%) 1 (2.1%)
The severity of adverse events was graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events, version 4.02. No grade 4 adverse events were reported. One 
death was determined by the investigators to be related to ipilimumab (inflammatory colitis with 
bowel perforation).
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more than half of the patients received ipilimumab as third or fourth line therapy. 
Then again, all patients showed progressive disease on ipilimumab, including the 
patients who received ipilimumab as second line treatment. So, besides the rare 
long-lasting clinical responses of DC vaccination in stage IV melanoma, the 
results of this study point out that monotherapy DC vaccination before ipilimumab 
is not preferred in stage IV patients. As an alternative, DC vaccination might be a 
good option as combination-therapy with ipilimumab in stage IV melanoma 
patients, mainly due to its favourable toxicity profile and the fact that functionality of 
tumor-specific T cells induced by DC vaccination could be enhanced by blocking 
the immune checkpoint CTLA-4. 36 Murine studies support the concept that 
anti-CTLA-4 increases the frequency of activated T cells and causes a favourable 
effector T cell to regulatory T cell ratio. 37, 38 However, not all early human studies 
combining anti-CTLA-4 with different forms of vaccines showed positive 
immunological and clinical results. 36 This suggests that potent vaccines are 
required to benefit from the combination with anti-CTLA-4. DC vaccination has 
proven to be an effective method of inducing tumor-specific T cell responses. 25 
Wilgenhof and colleagues recently showed tolerability and encouraging 
anti-tumor activity, with an objective response rate of 38%, in a phase 2 study of 
autologous mRNA electroporated DCs in combination with ipilimumab in patients 
with pre-treated stage IV melanoma. 39 Further clinical investigation with the 
combination of DC vaccination and immune checkpoint inhibitors is warranted 
to determine its position in the treatment of advanced melanoma. The choice of 
antigens to load the DCs will probably become of great importance in these future 
trials, since recent findings showed that neoantigen-specific T cell reactivity may 
be critical to the effect of checkpoint blockade. 40 Carreno and colleagues showed 
it was possible to increase the breadth and diversity of melanoma neoantigen- 
specific T cells in peripheral blood samples of 3 advanced melanoma patients 
treated with a DC vaccine with carefully selected patient-specific neoantigens. 41   
 The immune-related adverse event profile of ipilimumab in patients pre- 
treated with DC vaccination is consistent with that reported in previous literature; 
immune-related adverse events of any grade were seen in 58% of patients in this 
study as compared to 61-70% of patients in phase 2 and 3 trials with ipilimumab. 
3, 42, 43 So, prior treatment with DC vaccination did not lead to more or worse 
immune-related adverse events. Patients with immune-related adverse events 
were treated by management algorithms with topical or systemic corticosteroids, 
and if necessary infliximab (anti-tumor necrosis factor α antibody) was given. 
Most immune-related adverse events were reversible with this approach, 
nevertheless one patient died due to a severe colitis with perforation.
 In conclusion, this retrospective study showed a good clinical response to 
ipilimumab among advanced melanoma patients with progressive disease after 
adjuvant DC vaccination for stage III disease, while the effect was very limited in 
patients who showed progression after DC vaccination for stage IV disease. 
However, it is too early to conclude that prior DC vaccination for stage III disease 
has an additional effect on ipilimumab when given after progression upon DC 
vaccination, despite the fact that these patients showed promising response rates. 
Furthermore, pre-treatment with DC vaccination did not seem to cause an 
aggravation of immune-related adverse events. A prospective randomized clinical 
trial with DC vaccination has to show at least a comparable clinical outcome with 
adjuvant ipilimumab to support the future choice of DC vaccination in stage III 
melanoma patients, preserving ipilimumab in case of progression. 
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The goal of dendritic cell (DC) vaccination is to induce antitumor T cell responses 
by administering DCs that are ex vivo activated and loaded with specific tumor 
antigens. Significant progress has been made in the field of human DC vaccines 
since the first clinical trial in 1996. 1 Melanoma is one of the tumor types in which 
DC vaccination has frequently been studied, mostly in small exploratory studies, 
but these studies have not yet led to a clear position of DC vaccination in the 
treatment of melanoma. The therapeutic options for stage IV melanoma have 
grown rapidly over the past years with the approval of immune checkpoint 
inhibitors blocking cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and 
programmed death 1 (PD-1), and targeted therapies, including inhibitors of BRAF 
en MEK. 2-9 Furthermore, several systemic treatments are currently investigated 
in stage III melanoma, of which ipilimumab (anti-CTLA-4) has recently been 
approved by the Food and Drug Administration (FDA). 10
 This thesis focuses on several aspects of DC vaccination in melanoma, 
including efficacy, toxicity, and combination treatment. As such, attempted to 
contribute to determine the position of DC vaccination in the treatment of stage 
III and stage IV melanoma patients in light of these approved treatment modalities.
Dendritic cell vaccination in stage III melanoma
In a retrospective study in 97 patients with stage III melanoma vaccinated with 
autologous monocyte-derived DCs (moDCs) following radical lymph node 
dissection (Chapter 2), we confirmed that DC vaccination is more effective in 
inducing (functional) tumor-specific T cells in stage III melanoma patients as 
compared to stage IV patients. Furthermore, we proved that performing additional 
cycles of vaccinations enhances the chance of a broader immune response. The 
challenge for the near future will be to prove if besides the effective induction of 
tumor-specific immune responses, adjuvant DC vaccination in stage III patients 
results in improved survival. A retrospective study already showed improved 
overall survival in stage III melanoma patients treated with adjuvant moDCs, 
when compared to matched controls treated with standard of care, a radical 
lymph node dissection. 11 Furthermore, the clinical results of DC vaccination need 
to be compared to other (potential) adjuvant treatments, like ipilimumab and 
anti-PD-1 monoclonal antibodies (mAbs). Our study with adjuvant DC vaccination 
showed comparable 3-year recurrence-free survival (RFS) rates in comparison 
with the EORTC phase 3 trial with adjuvant ipilimumab (43% in our cohort versus 
46.5% in the ipilimumab group); median RFS was 23.0 months in stage III patients 
treated with DC vaccination, compared to 26.1 months in the study with 
ipilimumab (Chapter 2). 10 The promising results of adjuvant DC vaccination in 
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stage III melanoma have to be confirmed in prospective clinical trials and 
compared to mature survival data of adjuvant ipilimumab and trials with 
adjuvant anti-PD-1 mAbs (NCT02388906, NCT02362594). 
 This thesis provides additional arguments to choose for adjuvant DC 
vaccination over immune checkpoint inhibitors in stage III melanoma patients 
when comparable survival rates will be found in future phase 3 clinical trials. 
First, it is of great importance to consider side effects in treatment decisions, 
especially when treatments are equally effective. Chapter 3 showed that the 
toxicity profile of DC vaccination is much more favorable compared to that of 
checkpoint inhibitors. 10, 12 The most common side effects of DC vaccination are 
grade 1-2 flu-like symptoms and injection site reactions, which correlates with the 
presence of antigen-specific (functional) T cell responses and improved overall 
survival in stage III and IV melanoma patients. In contrast to DC vaccination, 
adjuvant ipilimumab (10 mg/kg) results in significant grade 3-4 (immune-related) 
adverse events, e.g., colitis, dermatitis, hypophysitis and hepatitis. 10 This difference 
might be explained by the fact that DC vaccination induces an antigen- specific 
immune response instead of stimulating the immune system in general, which 
happens with immune checkpoint inhibitors. Second, the sequence of treatments 
in stage III and stage IV melanoma will become increasingly important with 
the rapidly growing field of therapeutic options. Patients with metastatic disease 
after prior adjuvant DC vaccination for stage III melanoma, showed good clinical 
responses to ipilimumab without aggravation of immune-related adverse events, 
which further supports the choice of DC vaccination in stage III patients, as 
ipilimumab can be preserved in case of progression (Chapter 5). Based on the 
mechanism of action of ipilimumab and DC vaccination, patients that are treated 
with ipilimumab might benefit from prior DC vaccination, despite progressive 
disease upon DC vaccination. These patients may have developed tumor-specific 
T cell responses upon DC vaccination that were not strong enough for disease 
control due to immunosuppressive counter mechanisms, but which could be 
enhanced by ipilimumab upon progressive disease. Phase 3 trials with ipilimumab 
in pre-treated and previously untreated metastatic melanoma patients showed 
2-year progression-free survival rates of approximately 10%, as compared to 35% 
in patients pre-treated with DC vaccination for stage III disease in our study. 2, 3 
Of course, based on this small retrospective study, it cannot yet be concluded 
that prior adjuvant DC vaccination for stage III disease has an additional effect on 
ipilimumab when given after progressive disease upon ipilimumab, however, 
these survival rates look promising in a population in which 67% of patients had 
M1c disease.
 Until now, all DC vaccination trials in stage III melanoma patients have been 
performed with moDCs. The production of DC vaccines is more labor-intensive 
and time-consuming compared to checkpoint inhibitors, especially in case of 
vaccines with moDCs. However, this problem is partly circumvented by the use of 
naturally circulating DCs, including myeloid DCs (mDCs) and plasmacytoid DCs 
(pDCs). The most important advantages of naturally circulating DCs over moDCs 
are a highly standardized rapid isolation procedure with antibody-coated 
magnetic beads (CliniMACS Prodigy), resulting in clinically applicable purified 
DCs and the absence of an extensive culture period (overnight versus 8-9 days in 
moDCs), which may have a positive effect on the immunogenicity of the cells. 13, 14 
This makes naturally circulating DCs more suitable for large scale multicenter 
application. Currently we are conducting a trial (NCT02574377) in which 
immunogenicity of combined adjuvant mDC and pDC vaccination versus 
adjuvant mDC or pDC vaccination alone is tested in stage III melanoma patients. 
Naturally circulating DCs have complementary functions and they can activate 
each other. Co-culture of mDCs and pDCs during activation augments the 
expression of co-stimulatory molecules and secretion of proinflammatory 
cytokines, providing the rationale for combining mDCs and pDCs in a DC vaccine. 15 
A prospective randomized placebo-controlled phase 3 clinical trial with naturally 
circulating DCs in stage III melanoma patients will start in 2016. The results of 
this trial will aid in positioning  of adjuvant DC vaccination as treatment for stage 
III disease. 
Dendritic cell vaccination in stage IV melanoma 
DC vaccination as monotherapy shows minimal clinical benefit in stage IV 
melanoma patients, despite the capability of inducing tumor-specific T cells. 16 
Additionally, this thesis showed that the clinical effect of ipilimumab was very 
limited in advanced melanoma patients who showed progression after prior DC 
vaccination for stage IV disease (Chapter 5). These results demonstrate that DC 
vaccination as monotherapy might not be preferred in the treatment of stage IV 
melanoma patients. 
 However, the clinical efficacy of DC vaccination in stage IV melanoma 
patients might be improved by combining it with other therapies that neutralize 
the immunosuppressive counter mechanisms induced by the tumor (micro-
environment), like release of immunosuppressive cytokines, induction of regulatory 
T cells (Tregs) and myeloid derived suppressor cells (MDSCs), and expression of 
immune checkpoint molecules, like CTLA-4 and PD-1. 17, 18 The mild toxicity profile 
of DC vaccination makes it an ideal candidate for combination treatment. 
We performed a prospective, randomized, open label, phase 2 study in stage III 
and IV melanoma patients receiving moDCs preceded by cisplatin or DC 
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vaccination alone (Chapter 4), as preclinical evidence showed that cisplatin has 
immunomodulatory effects, e.g., targeting Tregs, MDSCs and PD-L2 expression. 19, 
20 This trial showed that the combination of DC vaccination and cisplatin is 
feasible and safe, but did not result in improved immunological and clinical 
outcomes. This might be caused by several reasons, including the possibility that 
the immunomodulatory effects of cisplatin are not strong enough in vivo, the 
timing of cisplatin and vaccination might not have been optimal, and the 
immuno suppressive effects of the antiemetic dexamethasone might have 
dampened the anti-tumor immune response. An earlier trial combining DC 
vaccination with the anti-CD25 mAb daclizumab did not show an enhancement 
of the efficacy of the DC vaccine, despite inducing a depletion of Tregs in the 
peripheral blood, since residual daclizumab functionally suppressed de novo 
induced CD25+ effector cells. 21 Both studies were initiated before the availability 
of immune checkpoint inhibitors and targeted therapies. Combining DC 
vaccination with immune checkpoint inhibitors blocking CTLA-4 or PD-1 might 
be the most effective path to pursue in the near future, as a phase 2 trial of moDCs 
in combination with ipilimumab conducted by Wilgenhof and colleagues showed 
tolerability and an objective response rate of 38% in 39 heavily pre-treated 
advanced melanoma patients. 22 Clinical studies with the combination of DC 
vaccination and anti-PD-1 mAbs in melanoma patients have not been described 
yet, but preclinical data support a potential synergistic effect. 23 The most logical 
next step will be a prospective trial, which compares the combination of DC 
vaccination and an immune checkpoint inhibitor with the combination of 
ipilimumab and an anti-PD-1 mAb.
Future developments in dendritic cell vaccines
As abovementioned, an important breakthrough in DC-based immunotherapy is 
rapid and standardized production of DC vaccines with naturally circulating DC 
subsets, which enables multicenter trials. Besides the source of DCs, the antigens 
used in DC vaccination might influence the clinical effectiveness. Melanoma dif-
ferentiation antigens, like tyrosinase and gp100, are frequently used, as they are 
commonly expressed on melanoma cells. Furthermore, cancer-testis antigens 
(e.g., MAGE-A3) have been used to load DCs for vaccination of melanoma patients. 
24 Melanoma is the tumor with the highest prevalence of somatic mutations, 
resulting in the formation of many neoantigens, which have proven to play an 
important role in antitumor immunity. 25 These results formed the basis for a 
proof of concept study with a DC vaccine loaded with patient-specific neoantigens, 
which resulted in an enhanced CD8+ T cell response against some of these tumor 
neoantigens. 26 Although these results are promising, the biggest challenge of 
such a personalized vaccination strategy will be the identification of the optimal 
immunogenic neoantigens. 27 To induce a broad immune response, it might be 
best to combine melanoma differentiation antigens, cancer-testis antigens, and 
neoantigens in DC vaccines.  
In conclusion
DC vaccination is safe and adjuvant DC vaccination as monotherapy shows 
promising results in stage III melanoma patients after radical lymph node 
dissection, while in stage IV melanoma patients, DC vaccination might be more 
suited as combination treatment with immune checkpoint inhibitors. However, 
clinical effectiveness of DC vaccination as monotherapy in stage III melanoma 
still has to be proven in a prospective randomized phase 3 clinical trial that will 
start in 2016.
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Melanoom
Melanoom is een zeer agressieve vorm van kanker die voortkomt uit een kwaad - 
aardige ontaarding van pigmentcellen (melanocyten). Het melanoom kan worden 
onderverdeeld in 3 belangrijke subtypen: huidmelanoom, oogmelanoom en slijm - 
vlies melanoom. Het huidmelanoom is het meest voorkomende melanoom subtype 
(90%) en sinds de zestiger jaren stijgt de incidentie sneller dan elke andere 
kankersoort. Verschillende risicofactoren spelen een rol in de ontwikkeling van 
huidmelanomen, zoals cumulatieve zonexpositie, verbranden op jonge leeftijd, 
lichte huidskleur, en een hoog aantal (atypische) moedervlekken. Een grotere 
blootstelling aan ultraviolette straling is de belangrijkste reden voor de toenemende 
incidentie van huidmelanomen. Oog- en slijmvlies melanomen zijn zeldzamer en 
tonen een stabiele incidentie.
 Melanomen worden ingedeeld in verschillende stadia volgens een specifiek 
classificatiesysteem, gebaseerd op informatie van het primaire melanoom, lymf - 
klier betrokkenheid en de aanwezigheid van uitzaaiingen op afstand. Stadium I/
II melanomen behelzen alleen primaire melanomen zonder uitzaaiingen in lymf - 
klieren of op afstand. Patiënten met een stadium III melanoom hebben locoregionale 
lymfklier uitzaaiingen en/of in-transit uitzaaiingen, terwijl patiënten met een 
stadium IV melanoom uitzaaiingen op afstand hebben. De focus van dit proefschrift 
ligt op patiënten met een stadium III of IV melanoom en de rol van afweertherapie 
met gebruik van dendritische cellen.
Dendritische cellen
Dendritische cellen (DC) zijn in 1973 voor het eerst ontdekt door Ralph Steinman 
en Zanvil Cohn. DC spelen een zeer belangrijke rol in het immuunsysteem. Ze zijn 
continu op zoek naar ziekteverwekkers of weefselschade in het lichaam, om 
vervolgens deze ziekteverwekkers of celresten op te nemen. Nadat stukjes van 
ziekteverwekkers of dood celmateriaal zijn opgenomen, worden DC geactiveerd 
en verplaatsen ze zich via de lymfebanen naar lymfklieren. Aldaar presenteren 
DC kleine stukjes van de ziekteverwekkers, genaamd antigenen, aan naïeve 
T cellen. Deze T cellen gaan zich delen en differentiëren zich tot geactiveerde 
T cellen die in staat zijn om de ziekteverwekkers te doden op een antigeen-
afhankelijke manier. 
 Onder ideale omstandigheden wordt tumorgroei onder controle gehouden 
door een immuniteitscyclus (Figuur 1), die bestaat uit verschillende stappen. 
Allereerst worden tumorantigenen opgenomen door DC en gepresenteerd aan 
T cellen (stap 1). Dit leidt tot de aanmaak van tumorspecifieke T cellen in lymfklieren 
(stap 2). Deze T cellen infiltreren de tumor vanuit de bloedbaan (stap 3) en in de 
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tumor herkennen de T cellen de tumorcellen via de specifieke antigenen (stap 4). 
Door deze herkenning worden de tumorcellen gedood door de T cellen en komen 
er nieuwe tumorantigenen vrij (stap 5). Echter, deze cyclus wordt op meerdere 
manieren verstoord in kankerpatiënten: tumorantigenen worden niet als lichaams - 
vreemd herkend door DC, er vindt onvoldoende stimulatie van DC plaats, T cellen 
infiltreren de tumor onvoldoende, of factoren in de tumor(omgeving) onderdrukken 
geactiveerde T cellen, zoals immunosuppressieve cytokines/cellen en de expressie 
van remmende moleculen genaamd checkpoint moleculen (CTLA-4 en PD-1).   
Dendritische cel vaccins
In de strijd tegen kanker kunnen DC  als vaccin gebruikt worden om sommige van 
bovengenoemde verstorende factoren in de immuniteitscyclus te overkomen. 
Voor het maken van DC vaccins zijn de laatste jaren verschillende soorten cellen 
als bron gebruikt, die middels een speciale bloedafname (aferese) worden verkregen. 
Tot recent werden met name voorlopercellen (monocyten) gebruikt die buiten het 
lichaam tot DC gekweekt werden (moDC), maar sinds kort is het door efficiëntere 
isolatietechnieken ook mogelijk om in bloed voorkomende DC te isoleren, 
bestaande uit myeloïde DC (mDC) en plasmacytoïde DC (pDC). De verkregen DC 
worden vervolgens buiten het lichaam geactiveerd en beladen met antigenen die 
op het melanoom voorkomen. Tenslotte wordt het DC vaccin teruggeven aan de 
patiënt met als doel om tumorspecifieke T cellen te induceren die tumorcellen 
zullen doden. Meerdere studies bij melanoom patiënten in het verleden hebben 
al aangetoond dat zulke tumorspecifieke T cellen op te wekken zijn middels DC 
vaccinatie.
Therapeutisch landschap stadium III en IV melanoom
Klinische uitkomsten van nieuwe behandelingen voor stadium III en IV 
melanoom patiënten, inclusief DC vaccinatie, moeten vergeleken worden met de 
resultaten van al goedgekeurde behandelmogelijkheden. Het therapeutische 
landschap van stadium IV melanomen is sinds 2011 drastisch veranderd. Voor 
2011 bestond de behandeling van stadium IV melanoom uit chemotherapie of 
interleukine 2 (IL-2), maar beide behandelingen hebben een minimaal effect op 
de overleving, waarbij IL-2 ook nog erg toxisch is. Tijdens de laatste jaren zijn 
meerdere nieuwe geneesmiddelen goedgekeurd voor de behandeling van stadium 
IV melanomen, inclusief checkpoint inhibitoren en doelgerichte therapieën. 
Checkpoint inhibitoren zijn monoklonale antilichamen die moleculen blokkeren 
die T cel activatie remmen, zoals CTLA-4 (ipilimumab) en PD-1 (pembrolizumab en 
nivolumab). Studies met ipilimumab toonden langdurige overleving in ongeveer 
20% van de melanoom patiënten. Studies met anti-PD-1 antilichamen toonden 
zelfs tweemaal zoveel responsen als ipilimumab, maar de lange termijn  overle-
vingscijfers zijn nog niet bekend. De combinatie van ipilimumab en anti-PD-1 
antilichamen resulteert zelfs in objectieve responsen in bijna 60% van de 
patiënten, maar brengt wel een aanzienlijk risico op ernstige bijwerkingen met 
zich mee. BRAF is een kinase dat betrokken is bij celdeling. In 40-60% van de 
uitgezaaide melanomen is er sprake van een mutatie in het BRAF gen, waardoor 
er ongereguleerde celdeling optreedt. Dit proces kan geremd worden door 
selectieve BRAF remmers (doelgerichte therapie; vemurafenib, dabrafenib). Deze 
middelen hebben een significante verbetering laten zien van de overleving van 
stadium IV melanoom patiënten met een activerende BRAF mutatie. Responsen 
op BRAF remmers zijn echter in de meeste patiënten tijdelijk door verschillende 
resistentie mechanismen. Recent werd duidelijk dat het toevoegen van een MEK 
remmer (cobimetinib, trametinib) aan een BRAF remmer zorgt voor een verbetering 
van de overleving met responsen van 64-68% en een mediane progressie-vrije 
overleving van 9.3 tot 11.4 maanden. 
Figuur 1  Kanker immuniteitscyclus
Onder ideale omstandigheden zou er een zelfonderhoudende immuniteitscyclus zijn, bestaande uit 
meerdere stappen die leiden tot het ontstaan van tumorspecifieke T cellen die tumorcellen doden.
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 De meeste klinische studies met dendritische cel vaccinatie in stadium IV 
melanomen zijn uitgevoerd met moDC. Ondanks dat in deze studies antigeen-
specifieke immuunresponsen werden gevonden, waren klinische responsen beperkt. 
Recent zijn nog 2 kleine studies uitgevoerd met in bloed voorkomende DC, één 
studie met mDC en de andere met pDC. Tumorspecifieke T cellen werden in beide 
studies gevonden, maar ook hier werden in een minderheid van de patiënten 
objectieve responsen gezien. 
Stadium III melanoom patiënten hebben ondanks chirurgie een groot risico op 
recidief ziekte. Daarom zijn aanvullende behandelingen na chirurgie gewenst die 
de overleving significant verbeteren. Tot recent was interferon-α de enige 
goedgekeurde aanvullende behandeling bij stadium III melanoom, maar in 
Nederland en veel andere Europese landen wordt het niet aangeraden vanwege 
een minimaal effect op overleving en substantiële toxiciteit. Ipilimumab is in de 
VS onlangs goedgekeurd als aanvullende behandeling op basis van een verbeterde 
recidief-vrije overleving in een fase 3 studie. Echter, aanvullende behandeling 
met ipilimumab induceerde aanzienlijke toxiciteit en 52% van de patiënten heeft 
het geplande behandelschema niet voltooid.  Klinische studies met aanvullende 
anti-PD-1 antilichamen worden momenteel verricht.  
 DC vaccinatie is mogelijk meer effectief in stadium III melanoom patiënten 
dan in stadium IV patiënten, omdat deze patiënten een potenter immuunsysteem 
hebben door een lagere tumorload. Een retrospectieve analyse met 78 stadium III 
patiënten, behandeld met adjuvante moDC, toonde een significante verbetering 
van de overleving in vergelijking met een gematched cohort van 209 patiënten 
die alleen een radicale lymfklier dissectie ondergingen (63.6 maanden versus 31.0 
maanden). Deze resultaten moeten nog bevestigd worden in toekomstige studies. 
Bevindingen van dit proefschrift
Het doel van dit proefschrift is om inzicht te krijgen in de positie van DC vaccinatie 
in het kader van het snel ontwikkelende therapeutische landschap van stadium 
III en stadium IV melanomen. 
 Hoofdstuk 2 beschrijft de resultaten van een retrospectieve studie bij 97 
stadium III melanoom patiënten, waarin de immunologische effectiviteit van 
aanvullende moDC vaccinaties na chirurgie wordt onderzocht. Deze studie toonde 
aan dat DC vaccinatie effectiever is in het induceren van (functionele)  tumor - 
specifieke T cellen in stadium III patiënten in vergelijking met stadium IV patiënten. 
Daarnaast toonden we aan dat de kans op een bredere immuunrespons vergroot 
wordt door het verrichten van meerdere cycli van vaccinaties. Toekomstige 
prospectieve studies moeten uitwijzen of aanvullende DC vaccinatie in stadium III 
patiënten, naast de effectieve inductie van tumorspecifieke  immuunresponsen, 
leidt tot een verbeterde overleving. Daarnaast zullen de resultaten van die studies 
vergeleken moeten worden met andere (potentiële) aanvullende behandelingen, 
zoals ipilimumab en anti-PD-1 antilichamen.
 Het is belangrijk om bijwerkingen van een behandeling te betrekken in de 
keuze van het beste individuele behandelplan van elke patiënt, met name als 
behandelingen even effectief zijn of wanneer combinaties van behandelingen 
overwogen worden. In hoofdstuk 3 wordt het toxiciteitprofiel van DC vaccinatie 
als monotherapie beschreven in een groot cohort van stadium III en IV melanoom 
patiënten. De meest voorkomende bijwerkingen van DC vaccinatie zijn milde 
griepachtige verschijnselen en injectieplaats reacties. Het optreden van deze 
bijwerkingen correleert met de aanwezigheid van tumorspecifieke (functionele) 
T cel responsen en verbeterde overleving in stadium III en IV melanoom patiënten. 
DC vaccinatie geeft veel minder bijwerkingen heeft dan checkpoint inhibitoren, 
wat mogelijk verklaard kan worden door het feit dat DC vaccinatie een antigeen-
specifieke immuun respons induceert in plaats van het stimuleren van het 
immuun systeem in het algemeen, zoals gebeurt bij immuun checkpoint inhibitoren. 
 De immunologische en klinische effecten van DC vaccinatie kunnen mogelijk 
verbeterd worden door combinatie met andere therapieën. Het milde toxiciteit-
profiel van DC vaccinatie maakt het een ideale kandidaat voor combinatie 
behandeling. In hoofdstuk 4 onderzoeken we in een prospectieve, gerandomi-
seerde fase 2 studie of de combinatie van DC vaccinatie en cisplatin, een vorm 
van chemotherapie, in stadium III en IV melanoom patiënten klinisch haalbaar 
en veilig is, en of het tot betere immunologische en klinische responsen leidt. 
De keuze voor de combinatie met cisplatin komt voort uit de recente ontdekking 
dat cisplatin ook immunologische effecten heeft, die mogelijk een positief effect 
hebben op tumorspecifieke T cellen, die geïnduceerd worden door DC vaccinatie. 
De studie toonde aan dat de combinatie van DC vaccinatie en cisplatin veilig en 
haalbaar is, maar dat er geen verbetering werd gezien van immunologische en 
klinische uitkomsten. Dit kan verschillende oorzaken hebben: de immunologische 
effecten van cisplatin zijn mogelijk niet sterk genoeg,  de timing tussen cisplatin 
en DC vaccinatie was mogelijk niet optimaal, en het gebruik van dexamethason 
tegen de misselijkheid rondom cisplatin kan de antitumor respons hebben 
onderdrukt. Het combineren van DC vaccinatie en checkpoint inhibitoren is de 
meest logische volgende stap.
 De effectiviteit van verschillende behandeling wordt mogelijk beïnvloed 
door de volgorde van deze behandelingen. Hoofdstuk 5 beschrijft de effectiviteit 
van ipilimumab in stadium IV melanoom patiënten die progressieve ziekte 
vertoonden na DC vaccinatie, dat gegeven was als aanvullende behandeling na 
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chirurgie voor stadium III melanoom of voor stadium IV melanoom. Patiënten 
met een stadium IV melanoom na eerdere aanvullende DC vaccinatie voor 
stadium III melanoom, toonden een goede klinische respons op ipilimumab 
zonder toename van immuungerelateerde bijwerkingen. Dit ondersteunt de keuze 
voor DC vaccinatie in stadium III melanoompatiënten, aangezien ipilimumab 
achter de hand gehouden kan worden tot het optreden van progressie. Echter, 
de klinische effecten van ipilimumab waren erg beperkt in gemetastaseerde 
 melanoompatiënten die eerder DC vaccinatie hadden gekregen voor stadium IV 
melanoom. Dit is een extra argument dat DC vaccinatie monotherapie niet 
geprefereerd wordt in de behandeling van stadium IV melanoom patiënten, naast 
het feit dat DC vaccinatie beperkte klinische responsen laat zien in deze 
 patiëntenpopulatie. 
Tot slot
De resultaten van dit proefschrift laten zien dat DC vaccinatie veilig is en dat 
aanvullende DC vaccinatie als monotherapie veelbelovende resultaten laat zien 
bij stadium III melanoom patiënten na radicale chirurgie, terwijl DC vaccinatie 
mogelijk meer geschikt is om te combineren met immuun checkpoint inhibitoren 
bij stadium IV melanoompatiënten. Echter, de klinische effectiviteit van DC 
vaccinatie bij stadium III melanoompatiënten moet nog bewezen worden in een 
gerandomiseerde fase 3 studie, die eind 2016 zal starten. In deze studie zullen 
de van nature voorkomende dendritische cel subtypen (mDC en pDC) gebruikt 
gaan worden, omdat daarmee een sneller en meer gestandaardiseerd productie 
proces kan plaatsvinden. 
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dit dankwoord beginnen met het bedanken van alle patiënten en hun families 
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Vervolgens wil ik de leden mijn promotieteam bedanken met wie ik fijn heb 
samengewerkt. Jullie verschillende kwaliteiten vullen elkaar goed aan. Professor 
Gerritsen, beste Winald, ik heb het als zeer prettig ervaren dat jouw deur altijd 
open stond voor overleg. De vele ideeën op vrijdagochtend tijdens het wekelijkse 
promotieoverleg zijn befaamd onder de DC vaccinatie onderzoekers. Ik zal je mooie 
toespraak op mijn bruiloft ook nooit vergeten. Professor de Vries, beste Jolanda, 
jij bent een perfect voorbeeld van efficiënt werken en daar heb ik tijdens mijn 
promotie veel van geleerd. Het is bewonderenswaardig hoe jij de afgelopen jaren 
de drijfveer bent geweest naar de huidige fase 3 studie met DC vaccinatie bij 
 melanoompatiënten. Dit werkt enorm stimulerend voor promovendi die met je 
samenwerken!
Gerty, jouw goede adviezen hebben zeker geleid tot het huidige resultaat van 
dit proefschrift. Ondanks alle drukte kreeg je het altijd voor elkaar om als één 
van de eersten met feedback op artikelen te komen. Vooral je duidelijke uitleg 
op immunologisch vlak hebben mij zeer geholpen. Kalijn, wat een snelheid, op 
1 september zelf gepromoveerd en nu al copromotor van mijn proefschrift. Dit is 
helemaal terecht, want je hebt me enorm geholpen bij de totstandkoming van 
dit proefschrift. Je bent een van de locomotieven van de DC vaccinatie trein, een 
prettige collega en gezellige kamergenoot!
De leden van de manuscriptcommissie, Prof. dr. de Wilt, Prof. dr. v.d. Kerkhof en 
dr. v.d. Eertwegh, wil ik bedanken voor het beoordelen van dit proefschrift.
De DC vaccinatie trein bestaat verder nog uit meerdere onderzoekers. Beste Harm, 
ik geniet nog steeds van je eeuwige positivisme en droge humor. Een kort 
telefoontje monde altijd uit in lange gesprekken over van alles en nog wat! Beste 
Martine, oftewel “de nieuwste musketier” zoals Winald altijd zegt, ik heb er alle 
vertrouwen in dat de fase 3 studie bij jou in goede handen is.  Een kamer delen met 
Maarten van der Doelen en mij is al een goede vuurdoop geweest, denk ik zo.    
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Studies met cellulaire producten vragen enorm veel inspanning van alle betrokkenen. 
Ik heb heel veel bewondering voor de analisten van het TIL, die allemaal erg hard 
werken en flexibel zijn om de studies draaiende te houden. Nicole,  altijd vrolijk 
ondanks alle drukte en de vele vragen die ik had (sorry ik ken alleen 14078 uit 
mijn hoofd). Jeanette, wat een arbeidsethos heb jij, overwerken zodat een vaccin 
toch gemaakt kon worden was voor jou geen probleem. Tom, de hardloper van het 
stel, met een Y-chromosoom zorg je voor een goede balans tussen alle vrouwen. 
Mandy, altijd meedenkend als wij dokters weer een nieuwe patiënt ergens tussen 
wilden plannen. Annemiek, zonder jou hadden we het artikel betreffende de 
DTH data niet kunnen voltooien. Michel, inmiddels in Utrecht, maar nog steeds 
befaamd voor alle KLH data. Tenslotte Tjitske, dank voor de FACS cursus, die mijn 
inzicht zeker heeft doen verbreden. 
Van de afdeling Medische Oncologie moet ik natuurlijk ook meerdere mensen 
bedanken. Alle villabewoners van zowel de Villa Interna als Villa Externa, 
bedankt voor de leuke tijd. De deuren stonden altijd open en de lunches waren erg 
gezellig met alle PhD’s, waaronder Janneke, Chantal, Eline, Simône, Annelieke, 
Myrella, Mark, Maarten, Harm en Martine. Ook alle stafleden bedankt; als 
fellow leer ik momenteel erg veel van jullie. Winette, Koos bedankt voor jullie 
begeleiding als opleider. Rutger, de melanoomexpert binnen de groep. Ik geniet 
altijd van je ongezouten mening en humor. Ik bewaar de foto met de roze 
driewieler voor jouw promotie. Alle fellows, ik voel me inmiddels al helemaal 
op mijn plek in jullie midden. Iedereen van het secretariaat, poli Rood en 
dagbehandeling bedankt voor de hulp bij de moeizame planningen en eindeloze 
verzoeken! Ik wil een aantal mensen in het bijzonder noemen: Natascha, jij bent 
mijn ogen in de mail van Winald. Esther, jij bent er altijd voor hulp en een praatje. 
Ine en Riet, DC vaccinaties op de dagbehandeling zijn onlosmakelijk verbonden 
aan jullie namen.  
Bij de klinische studies waren uiteraard nog vele andere afdelingen betrokken. 
Natuurlijk geen DC product zonder aferese via de afdeling Hematologie. Gaby & 
Corry,  en alle andere collega’s, hartelijk dank voor de fijne en vooral flexibele 
samenwerking. Via de afdeling Heelkunde (Hans, Han, Annelies) zijn veel 
patiënten in de DC vaccinatie studies terecht gekomen. Voordat patiënten 
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(Anna, Jeanine, Monique), Radiologie & Nucleaire Geneeskunde (Roel) en 
Dermatologie (Wilmy en Michelle) bedanken voor de fijne samenwerking.
Alle werknemers van het TIL bedankt voor de aangename en leerzame werksfeer. 
De meetings, soesjes en uitjes dragen bij aan een plezierige promotietijd. Van de 
befaamde kerstfeesten kunnen veel afdelingen nog wat leren! Carl, als hoofd van 
het TIL, heb je natuurlijk een bijdrage aan dit proefschrift geleverd. 
Daarnaast wil ik graag de opleiders van de Interne Geneeskunde in het 
Radboudumc bedanken. Professor de Graaf, beste Jacqueline, jouw inzet voor de 
opleiding Interne Geneeskunde is super!
Beste paranimfen, Mike, natuurlijk sta jij hier vandaag naast mij. Als grote broer 
en goede vriend sta je altijd voor mij klaar! Getuige op mijn bruiloft en nu een 
steun bij mijn promotie. Bedankt! Beste Chantal, wat een lange weg hebben wij 
al samen afgelegd: van carpoolen naar Tilburg, promoveren in de Villa, tot 
kamergenoten als fellow. Maar ook gezellige etentjes en concerten van Coldplay 
en Adele.
Lieve familie en vrienden, bedankt voor al jullie steun en interesse de afgelopen 
jaren. Nu kunnen jullie eindelijk zien waar ik me al die tijd mee bezig heb 
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geleid tot waar ik nu sta. Ik hou van jullie!
Allerliefste Malou, de laatste woorden zijn natuurlijk voor jou. Jij bent mijn 
rustpunt in alle drukte en zonder jou had ik dit proefschrift nooit zo snel kunnen 
afronden. Ik ben er enorm trots op dat jij mijn vrouw en de aanstaande moeder 
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superveel van jou!
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